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1. INTRODUCTION 
                   Delivery of medication to the human eye is an integral part of medical 
treatment.
1
 Ophthalmic drug delivery is one of the most interesting and 
challenging endeavors facing the pharmaceutical scientist. The anatomy, 
physiology, and biochemistry of the eye render this organ highly impervious to 
foreign substances. A significant challenge to the formulator is to circumvent the 
protective barriers of the eye without causing permanent tissue damage. 
Development of newer, more sensitive diagnostic techniques and novel 
therapeutic agents continue to provide ocular delivery systems with high 
therapeutic efficacy.
2
 
Ophthalmic preparations are specialized dosage forms designed to be 
instilled onto the external surface of the eye (topical), administered inside 
(intraocular), adjacent to the eye (periocular) or used in conjunction with any 
special device.  
The preparation may have any several purposes like therapeutic, 
prophylactic or palliative. The versatility of dosage form enables therapeutic 
agent to be suitable for function of preparation. Therapeutically active 
formulation may be designed to provide extended action for either convenience or 
reduction in dose frequency, improved bioavailability of an agent or improved 
delivery to target tissue. The residence time of an ocular preparation may range 
from few seconds (ophthalmic solutions) to hours (gel, ointments), to months or 
years (intra ocular or periocular dosage forms).  
Ophthalmic preparations are similar to parentral dosage form in their 
requirements for sterility as well as consideration for osmotic pressure (tonicity), 
preservation, and tissue compatibility, avoidance of pyrogens and particulate 
matter and suitable packaging. 
Widely used topical ophthalmic therapeutic dosage forms are solutions 
and suspensions. Ophthalmic solutions are most often multidose product 
containing suitable preservatives to meet compendial Preservative Efficacy Test 
(USP, BP, Ph Eu, and JP) requirements.  
Drugs are administered to the eye for local effects such as bacterial 
infection, miosis, mydriasis, or to reduce intraocular pressure.
3
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 Recent Trends in Ophthalmics 
     Various ophthalmic formulations include aqueous solution, aqueous 
suspension, ointments, and ocular inserts. Every ophthalmic product must be sterile 
in its final container to prevent the microbial contamination of the eye.   
Ophthalmic Solutions:  
               By definition, it is common, ingredients are completely soluble such that 
dose uniformity is not an issue and there is no or very little physical interference 
with vision. 
Advantages 
The advantages of ophthalmic solutions includes 
a. Easy manufacturing and low cost as compared to other dosage design. 
b. Ophthalmic solutions have potentially better dose uniformity. 
c. More ocular bioavailability.4 
Qualities:  
 Ophthalmic solution must 
a. Improve the ratio of local activity versus systemic effects. 
b. Be easy to self-administer. 
c. Not induce a foreign-body sensation, long-lasting blurring, or a very                       
bad aftertaste. 
d. Be sterilizable at industrial scale by a recognized process. 
e. Not rely on “exotic” ingredients like new chemical entities or difficult-to-source 
excipients (unless this is a key element). Preferably, excipients should have a drug 
master file and history of safe use for humans. 
f. Be compatible with an efficient antimicrobial preservative, or packaging. 
g. Preferably be stored without specific conditions. 
Gel forming Solutions:    
            Ophthalmic solutions usually aqueous based, which contain a polymer 
system that has low viscosity, aqueous in container and gels on contact with tear 
fluid. 
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 Powders for Solutions:  
 Drugs that have limited stability in aqueous solution can sometimes be 
prepared as sterile powder for reconstitution by pharmacist prior to dispensing. 
Reconstitution must be done with sterile vehicle. 
 Ophthalmic Suspension:  
 Ophthalmic Suspensions are finely divided, relatively insoluble drug 
substances in an aqueous vehicle containing suitable suspending and dispersing 
agent. 
 Because of tendency of particles to be retained in cul-de-sac, the contact time 
and duration of action of suspension could be theoretically exceeds. The drug is 
absorbed from solution and the solution concentration is replenished from retained 
particles. Optimum activity should be result from optimum particle size. 
 Ophthalmic ointments: -  
 Ophthalmic ointments are primarily anhydrous and contain mineral oil and 
white petrolatum as the base ingredients that can be varied in proportion to adjust 
consistency. In effort to maintain longer contact between drug and ophthalmic 
tissue, ointments have been used. Ophthalmic ointments tend to keep the drug in 
contact with eye longer than suspension and solution. Most ophthalmic ointments 
are mixture of mineral oil and white petrolatum and have melting point closed to 
body temperature. Sometime anhydrous Lanoline is used to take up an ingredient 
that was dissolved in small amount of water to affect dissolution. The aqueous 
solution incorporated into Lanoline and then the Lanoline is mixed with remaining 
ointment base ingredients.   
 Ointment must be non-irritating and free from grittiness so micronized form 
of the ingredients is required. The ointments are packaged in a sterile container 
such as an ointment tube. 
Disadvantages  
The disadvantages of ophthalmic ointments are 
a. drug content non uniformity. 
b. blurred vision due to sticky vehicle. 
c. not removed easily by tear fluid.  
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d. only bedtime administration.5 
The anhydrous nature of base enables use as carrier for moisture sensitive 
drugs.  
 Emulsions:  
 Ophthalmic emulsions offers advantage of being able to deliver poorly water 
soluble drug in solubilised form as an eye drop. Emulsions are used to deliver 
drugs (cyclosporine) topically for treatment of chronic dry eye condition.
6
  
 Ocular Gel:  
 Gel forming polymers such as carbomers have been used to develope 
aqueous semisolid dosage form which are packaged and administered same as 
ointments. eg.: Carbomer gel of Pilocarpine administered at bed time has been 
shown to prolong the intraocular pressure lowering effect in patient for up to 24 
hours.
7
 
 Ocular inserts:  
 Ocular inserts delivers the drug to eye by diffusional mechanism. Solid 
dosage form delivers an ophthalmic drug at a near constant known rate. The 
delivery of Pilocarpine by such an inserts was commercialized in 1975 (Ocusert 
Pilo) by Alza corporation. Ocusert is designed to be placed in a lower cul-de-sac 
to provide weekly dose. 
 Erodible inserts are developed (Lacrisert) for the treatment of dry eye. No 
preservative for unit dose required.
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 Delivery route for ophthalmic solution: 
   Conventionally, many ocular diseases are treated with either topical or 
systemic medications. Topical application of drug has remained the most 
preferred method due to ease of administration and low cost. Topical application 
is useful in the treatment of disorders affecting the anterior segment of the eye. 
Anatomical and physiological barriers hinder drugs from reaching posterior 
segment of eye mainly choroid and retina. A major fraction of drug following 
topical administration is lost by lacrimation, tear dilution, nasolacrimal drainage, 
and tear turnover. Such precorneal losses result in very low ocular bioavailability. 
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Typically, less than 5% of total administered dose reaches aqueous humor. So in 
order to maintain minimum inhibitory concentrations, the agents need to be 
frequently dosed. 
  Upon topical instillation drugs are absorbed by corneal route                              
(cornea → aqueous humor → intra ocular tissue) or non corneal route        
(conjunctiva → sclera → choroid/ retinal epithelial pigment). The preferred route 
depends mainly on the corneal permeability of drug molecules. Unlike topical 
administration, systemic dosing helps in the treatment of disease affecting 
posterior segment of the eye. A major drawback associated with systemic 
administration is only 1-2% of administered drug reaches to vitreous cavity. 
Blood retinal barrier which is selectively permeable to more lipophillic molecules 
mainly governs the entry of drug molecules into posterior segment of the eye. 
This results in frequent administration of high amounts of drugs leading to 
systemic side effects.
9
  
 
 
 
Figure 1: Human eye Anatomical structure 
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 About  drug 
 Beta blockers (β-blockers, beta-adrenergic blocking agents, beta 
antagonists, beta-adrenergic antagonists, beta-adrenoreceptor antagonists, or beta 
adrenergic receptor antagonists) are a class of drugs. 
            Beta blockers target the beta receptor. Beta receptors are found on cells of 
the heart muscles, smooth muscles, airways, arteries, kidneys, and other tissues that 
are part of the sympathetic nervous system and lead to stress responses, especially 
when they are stimulated by epinephrine(adrenaline). Beta blockers interfere with 
the binding to the receptor of epinephrine and other stress hormones, and weaken the 
effects of stress hormones. 
            In 1962, Sir James W. Black found the first clinically significant beta 
blockers - propranolol and pronethalol; it revolutionized the medical management 
of angina pectoris
 
and is considered by many to be one of the most important 
contributions to clinical medicine and pharmacology of the 20th century.
10 
 
              First beta-blocker approved for topical use in treatment of glaucoma in the 
USA (1978). With monotherapy, it depresses Intra ocular pressure to 18-34% 
below baseline within first few treatments. In its ophthalmic form, Timolol is used to 
treat open-angle and occasionally secondary glaucoma by reducing aqueous humour 
production through blockage of the beta receptors on the ciliary epithelium.
11 
 
 Classification of β- Blockers12 
        The β- blockers are classified based on their selectivity towards the 
Adrenergic receptors. They are classified as 
1.Non Selective agents 
             These are also called First Generation agents which include Propranolol, 
Pindolol, penbutlol, Timolol, and Sotalol etc,..  These are well absorbed orally 
and Effectively reduse the hyper tension at various organs.  
 
7 
 
2.β-1 selective agents 
           The second generation β- blockers or β-1 selective agents are cardio selective 
drugs and do not cause side effects in any site except the heart (site of mechanism). 
They are Atenolol, Betaxolol, Bisoprolol, Esmolol, and Metoprolol, etc,.. 
3. β-blockers with Vasodilator action 
          These Third generation β blockers lower the peripheral resistance either by β-
2 receptor stimulation or by direct vasodilation. i.e Dilevalol. 
The β-2 and β-3 selective agents have no significant clinical applications. Used in 
experimental purposes only. 
 
 GLAUCOMA : 
              Glaucoma is an eye disease in which the optic nerve is damaged in a 
characteristic pattern. This can permanently damage vision in the affected eyes 
and lead to blindness if left untreated. It is normally associated with increased 
fluid pressure in the eye (aqueous humour). The term "ocular hypertension" is 
used for people with consistently raised intraocular pressure (IOP) without any 
associated optic nerve damage. Conversely, the term 'normal tension' or 'low 
tension' glaucoma is used for those with optic nerve damage and associated visual 
field loss, but normal or low IOP. 
There are totally six types of Glaucoma 
 Primary open angle Glaucoma 
 Angle closure glaucoma 
 Normal tension Glaucoma 
 Pigmentary Glaucoma 
 Secondary Glaucoma 
 Congenital Glaucoma 
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                  In most cases, glaucoma is associated with higher-than-normal pressure 
inside the eye (ocular hypertension). If untreated or uncontrolled, glaucoma first 
causes peripheral vision loss and eventually can lead to blindness. 
                 According to the American Academy of Ophthalmology (AAO), the most 
common type of glaucoma is called primary open-angle glaucoma which affects 
an estimated 2.2 million people in the United States, and that number is expected 
to increase to 3.3 million by 2020 as the U.S. population ages. 
                The Ophthalmic solution of timolol maleate is the best available 
formulation which is Primarily used for Chronic Open angle glaucoma. 
 Formulation Parameters for Ophthalmic Solution 
   Ophthalmic solutions should be prepared and preserved according to whether 
they are to be used in surgical procedures, in clinic or office or by the patient at 
home. 
      There is an optimum pH level at which the solution of individual drugs 
should be buffered in order to obtain the maximum efficiency and stability. 
Deterioration of the drugs used is greatly diminished when they are dispensed at 
proper pH. 
   Preservative solutions in proper strength have been shown to be adequate for 
preservation of ophthalmic solutions.
13
 
                  Important factors to be considered in formulating an ophthalmic solution 
include the following 
 Clarity   
 Sterility. 
 Osmolarity. 
 pH, buffering. 
 Preservation. 
 Solubility. 
 Stability in appropriate vehicle. 
 Viscosity. 
 Suitable packaging and storage of finished product.14 
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 Clarity:  
 Ophthalmic solutions contain number of dissolved ingredients and are 
essentially free from foreign particles. Clarity of the solution may be enhanced by 
filtration. Ophthalmic solutions must be filtered in clean surroundings and laminar 
flow hood. 
Both container and closure must be thoroughly clean sterile and non 
shedding, neither contributing particulate matter to the solution during prolong 
contact for the duration of shelf life. The European Pharmacopoeia describes 
visual clarity and recommended standard that can be used for clarity 
specification. 
Particulate matter consists of mobile randomly sourced extraneous 
substances, other than gas bubbles, that cannot be quantitated by chemical 
analysis because of the small amount of material they represent and because of 
their heterogeneous composition. The tests described in USP are physical tests 
performed for the purpose of enumerating extraneous particles within specific 
size ranges. Ophthalmic preparation that are suspension, emulsions, or gels are 
exempt from these requirements. 
Light Obscuration and Microscopic procedure are specified in USP.
15 
 
Table 1: Light Obscuration Test Particle Count 
Parameter Diameter 
Particle size ≥10 µm ≥25 µm 
Number of particle 50 per ml 5 per ml 
  
 
Table 2: Microscopic Method Particle Count 
Parameter Diameter 
Particle size ≥10 µm ≥25 µm ≥50 µm 
Number of particle 50 per ml 5 per ml 2 per ml 
 
 
 
10 
 
 Sterility:   
 Sterility is defined as absence of viable microbial contamination. Sterility is 
an absolute requirement of all ophthalmic formulation. Contaminated ophthalmic 
formulation may result in eye infection that could ultimately cause blindness, 
especially if Pseudomonas aeruginosa microbes are involved. Therefore, 
ophthalmic formulations must be prepared in Laminar flow hood using aseptic 
technique just same as intravenous formulations. The sterile formulations must be 
packed in sterile containers. 
 Products to be instilled into the eye, while not parenterals by definition have 
many similar and often identical characteristics. The formulation of stable 
therapeutically active ophthalmic preparation requires high purity of ingredients 
as well as chemical, physical (particles), and microbial contaminants.
16
  
 
 Osmolarity:   
 Osmolarity is measure of osmoles of solute per liter of solution, while 
osmolality is measure of osmoles of solute per kilogram of solvent. Tonicity refers 
to the osmotic pressure exerted by salts in aqueous solution. Osmolarity and 
tonicity are not the same. The key difference between two is osmolarity is 
measure of all solutes in solution, whereas tonicity is measure of impermeable 
solute. Osmolarity compares the solute in two solutions, whereas tonicity 
compares the osmotic pressure gradient. An ophthalmic solution is isotonic with 
solution when the magnitude of colligative properties such as osmotic pressure, 
freezing point depression, boiling point elevation and vapour pressure is same. 
The derivatives of the terms: Iso osmotic, Hyper osmotic and Hypo osmotic 
should not be confused with Isotonic, Hypertonic and Hypotonic.
17
 
   Actuality, the external eye is much more tolerant of tonicity variation. 
Normal human plasma has an osmolality in the range of 285-295 milliosmol/ kg. 
Pharmaceutical solutions which have an osmolality higher than 600 milliosmol/ 
kg cause crenation (shrinking) of blood cells and significant pain. Whereas 
solutions which have osmolality less than about 150 milliosmol/ kg cause 
Haemolysis (rupture) of blood cells. Normal plasma osmolality is tightly 
controlled by homeostatic mechanisms in the body; a change of 3 milliosmol 
11 
 
represents a change from minimal to maximal ADH output. Thus, osmolality 
plays a role in formulation development. 
   Changes in osmolality can be used as guide to the breakdown of a substance 
in solution and is therefore used in stability testing.
18
 
  Osmolarity cannot be measured but it is calculated theoretically from the 
experimentally measured value of osmolality. Sometimes, osmolarity 
(mOsmol/L) is calculated theoretically from Molar concentration of dissolved 
solute and depends on dissociation constant of solution and deviation from 
ideality. The osmolality of a solution is commonly determined by the 
measurement of freezing point depression of solution. 
  Commonly used tonicity modifiers are Sodium chloride(0.9%), Boric acid 
(1.9%) and Dextrose (5%).
19
 
 pH and Buffering:   
 The physiologic pH of blood and tears is approximately 7.4. Eye can tolerate 
preparation of pH as low as 3.5 and as high as 9.0. It is preferable to formulate as 
close to physiological pH values to minimize the pH induced lacrimation, eye 
irritation and discomfort.
20
  
 Another important consideration in selection of optimum pH formulation is 
the drug stability for pH sensitive drugs such as peptides and proteins. pH may 
affect the function of the other components in formulation. For example The 
antimicrobial preservative, parabens are inactivated at alkaline pH and more active 
as the pH becomes acidic. 
 A variety of regulatory approved buffers are available covering the useful pH 
range to maintain the pH of the formulation. For acidic pH adjustment, acetic acid 
/sodium citrate are often employed. For alkaline pH phosphate or borate buffer are 
frequently used.
18
  
 Preservation:  
 Topically applied ophthalmic products, regardless of their use, usually 
contain water as one of primary component. This water provides a medium in 
which microorganisms can survive or grow. Other ingredients in these 
formulations can also create viable growth medium for these organisms.  
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 Hence such formulations usually contain preservative system. Preservative 
system can be either a single agent or combination of agents.    
  An ideal preservative should have broad spectrum of activity against all 
types of microorganisms, including yeast, mold, fungi, gram positive and gram 
negative bacteria.  The preservative is also ideally effective at low concentration 
to minimize expense, to avoid irritation and/or sensitization reaction. Agent 
should be stable over wide range of conditions including autoclaving temperature 
and pH range. Compatibility should establish with other component of 
preparation and with packaging system.
21
  
 
1. Types of Preservatives:  
 There are several preservatives, but only a few are used frequently in topical 
ophthalmic preparation. (Table-3) Preservatives typically work by one of two basic 
mechanisms: they are either detergents or act through oxidative processes. 
Detergents (or, more specifically surfactants) act by dissolving or disrupting lipids. 
Detergent preservatives kill microorganisms by disrupting cell membranes and 
causing cell lyses. Example includes Benzalkonium chloride (BAK or sometimes 
BKC), polyquaternium-1 (PQ1), alcohol preservatives, and phenols. 
 Oxidative preservative cause oxidative reaction that disrupt cellular 
metabolism. Examples of oxidative preservative include thiomersal, sodium 
perborate, sorbic acid, and chlorhexidine.
22
  
 
 
Table 3: Common Preservatives Used For Ophthalmic Solutions 
Compound class Example 
Quaternary ammoniums Benzalkonium chloride (BAK), Polyquaternium-1 
Mercurials Thiomersal, Phenyl mercuric nitrate, Phenyl 
mercuric acetate 
Alcohols Chlorbutanol, Benzyl alcohol 
Carboxylic acid Sorbic acid 
Phenols Methyl/propyl paraben 
Amidines Chlorhexidine 
Other Disodium EDTA 
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 Specific chemicals which are toxic to micro-organisms may be formulated in 
products which are not self-preserving and for which contamination with 
undesirable organisms is possible in use e.g. multi-dose vials, eye drops, nasal 
sprays, and topicals. The effectiveness of preservation (continuance of antimicrobial 
effectiveness) may depend on several factors 
  
2. Factors Affecting Preservative Activity :  
• Concentration (Dilution or Loss)  
• pH (Non-optimal range)  
• Temperature (Non optimal range)  
•Partitioning (Between aqueous and non-aqueous phases or between 
liquids/solids and headspace.)  
Effect of Concentration (Dilution) : 
Preservative dilution (loss) may be due to a number of factors  
• Chemical degradation  
• Biological degradation  
• Diffusion of volatile components through the packaging e.g. phenyl ethanol  
• Partitioning between the liquid and headspace phases  
• Absorption by the packaging e.g. plastic containers, benzalkonium chloride  
• Precipitation e.g. benzalkonium chloride with certain label adhesive 
components migrating through plastic bottles.  
 Investigations at the turn of the century demonstrated an exponential 
relationship between the rate of microbial death and the concentration of the 
antimicrobial agent, expressed as follows;   
                                                 C1
η 
t1 = C2
η 
t2 
                                                 
C1 and C2 represent the two concentrations of the antimicrobial agent and t1 
and t2 their respective times to achieve the same level of reduction in viable count. η 
is a measure of the effect of changes in the concentration (or dilution level) on the 
microbial death rate and is termed the concentration exponent or dilution coefficient. 
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In practical terms the activity of a compound with high η will be markedly 
decreased by dilution whilst a compound with low η will be less severely affected.  
 
Table 4: Relation of Concentration and Activity of the Preservative 
Concentration 
Exponent 
Fraction of Activity Remaining 
After Dilution to One Half 
1 ½ 
2 ¼ 
3 1/8 
4 1/16 
5 1/32 
6 1/64 
7 1/128 
8 1/256 
 
Preservative activity monitored by chemical assay may give very misleading data. 
 
 
Table 5: Preservative Characteristics 
Preservative agent Concentration exponent 
Benzalkonium chloride 3.5, 1.8(y), 9(m) 
Benzyl alcohol 6.6, 4(y), 2(m) 
Chlorocresol 8.3 
Parabens 2.5 
Phenol 5.8, 4(y), 4.3 (m) 
Phenoxyethanol 9 
Phenylethanol 5.6 
 
Note: y =  yeast, m= moulds, otherwise bacteria. 
 
Effect of pH  
The antimicrobial activity of many preservatives is strongly influenced by pH. The 
effect of pH on the antimicrobial activity is depicted in table 6. 
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Table 6: Effect of pH 
Preservative agent  Optimal pH range  
Benzalkonium chloride  4 – 10 
Benzyl alcohol  2 – 5 
Chlorocresol  < 8.5 
Parabens  3 - 9.5 
Phenol  <9 
Phenoxyethanol  <10 
Phenylethanol  <7 
 
A change in pH can have a significant effect on preservative efficacy e.g. the 
activity of phenol can be reduced by a factor of 10 by a change of one pH unit. 
Changes in pH of products may be the result of ageing or by the metabolic activity 
of a micro-organism resistant to the preservative. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Effect of Temperature : 
 The effect of temperature on preservative activity may be quantified in terms 
of the Q10 value (the change in activity for a 10°C change in temperature). Activity 
usually increases with temperature however preservative agents respond differently.                                                                                                                                                   
Contamination with resistant organism Growth; 
e.g.Pseudomonads 
Growth; Metabolism produces acidic 
metabolites 
pH change inactivates pH sensitive preservative 
Cross contamination with secondary 
opportunistic contaminant 
16 
 
 
 
Table 7: Effect of Temperature on Preservative Activity 
 
 
  
 
 
 
 
Effect of Partitioning : 
  For multi-phase systems e.g. creams, emulsions etc. effective 
preservation is complex. Partitioning of the preservative between the aqueous and 
oil phases may result in ineffective concentrations in the water phase. Surface active 
agents may need to be employed. Partitioning may also be affected by the pH of the 
product and the degree of ionization of the preservative.  
 
 Benzalkonium Chloride : 
   Benzalkonium chloride, a popular preservative for pharmaceutical 
products, is a complex mixture since the alkyl portion of the molecule is derived 
from natural sources. The chain lengths are principally C12 to C16, however the 
antimicrobial activity increases with the proportion of longer chain lengths. 
Unfortunately the tendency to adsorb to plastics also increases with chain length 
i.e. the most effective constituents of the mixture may be preferentially adsorbed. 
                                                        C8         C10 C12        C14 C16       C18 
                                    Content               <5%              >90%            <10% 
                                Anti-microbial  
                                  Activity  
                                  Adsorption 
 
Fig 2: Adsorption of Benzalkonium chloride 
Preservative agent        Temperature coefficient Q10  
Benzalkonium chloride  2.9-5.8  
Benzyl alcohol  2.3-7.2  
Chlorocresol  3-5  
Phenol  5  
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  Adsorption of benzalkonium chloride will therefore not only affect the 
available concentration in solution but will also affect the concentration 
distribution of the homologues. Both of these parameters will have significant 
microbiological effect even though chemical testing, which normally does not 
differentiate between homologues of BKC, may not reveal a significant change in 
total benzalkonium chloride.  
 
 Characteristics of Chemical Preservatives : 
• Range of antimicrobial activities  
• Structures, synonyms  
• Stability, compatibility  
 
Table 8:  Range of Antimicrobial Activities 
Preservative agent 
Bacteria 
Yeasts Moulds 
Gram-positive Gram-negative 
Benzalkonium 
chloride  
+++ ++ ++ + 
Benzyl alcohol  +++ + + + 
Chlorocresol  +++ ++ + + 
Parabens  ++ + ++ ++ 
Phenol  ++ + + + 
Phenoxyethanol  ++ +++ + + 
Phenylethanol  ++ +++ + + 
+++ Active  
++ Moderately Active  
 + Weakly Active.
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 Viscosity : 
 Viscosity measures the resistance of a solution to flow when a stress is 
applied. The viscosity of a solution is given in poise units. The unit centipoise (cp or 
the plural cps) is equal to 0.01 poise and is most often used in pharmaceutical 
applications. Compounds used to enhance viscosity are available in various grades 
such as 15 cps, 100 cps, etc. The grade number refers to the viscosities that result 
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when a fixed percentage aqueous solution is made. Generally the solutions are 1% or 
2% and the viscosity is measured at 20
o
C. 
Viscosity enhancers are used in ophthalmic solutions to increase their 
viscosity. This enables the formulation to remain in the eye longer and gives more 
time for the drug to exert its therapeutic activity or undergo absorption. Commonly 
used viscosity enhancers and their maximum concentrations are given in the table 
below. 
 
Table 9: List of Viscosity Enhancers 
 
 
 
 
 
 
 
 The most common viscosity desired in an ophthalmic solution is between 25 
and 50 cps. The actual concentration of the enhancer required to produce that 
viscosity will depend on the grade of the enhancer. For example, if methylcelluse 25 
cps is used, a 1% solution will create a viscosity of 25 cps. If methylcellulose 4000 
cps is used, a 0.25% solution provides the desired viscosity. Standard references 
give tables of viscosities produced by percentage solutions and grades of 
ingredients.
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 Sterilization of Ophthalmic Solution:   
 Methods of sterilization of ophthalmic solution 
Ophthalmic solutions can be sterilized by both terminal sterilization and 
filtration sterilization. Probably ophthalmic solutions packaged in plastic 
container are sterilized by filtration method. Both the methods are elaborated as 
follows.  
 
Viscosity Enhancer Maximum Concentration (%) 
Hydroxyethylcellulose 0.8 
Hydroxypropylmethylcellulose 1.0 
Methylcellulose 2.0 
Polyvinyl alcohol 1.4 
Polyvinylpyrrolidone 1.7 
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1. Terminal sterilization : 
Wherever possible, a process in which the product is sterilized in its final 
container (terminal sterilization) is chosen. 
 
I. Steam sterilization : 
Sterilization by saturated steam under pressure is preferred, wherever 
applicable, especially for aqueous preparations.  For this method of terminal 
sterilization the reference conditions for aqueous preparations are heating at a 
minimum of 121 °C for 15 min. 
 
II. Dry heat sterilization : 
Dry heat sterilization is carried out in an oven equipped with forced air 
circulation or other equipment specially designed for the purpose. For this 
method  the reference conditions are a minimum of 160 °C for at least 2 hrs. 
 
III. Ionizing radiation sterilization : 
Sterilization by this method is achieved by exposure of the product to 
ionizing radiation in the form of gamma radiation from a suitable radio isotopic 
source (such as cobalt 60) or of a beam of electrons energized by a suitable 
electron accelerator. For this method of terminal sterilization the reference 
absorbed dose is 25 kGy. 
 
IV. Gas sterilization : 
This method of sterilization is only to be used where there is no suitable 
alternative. It is essential that penetration by gas and moisture into the material to 
be sterilized is ensured and that it is followed by a process of elimination of the 
gas under conditions that have been previously established to ensure that any 
residue of gas or its transformation products in the sterilized product is below the 
concentration that could give rise to toxic effects during use of the product. 
 
2. Filtration Sterilization : 
Certain active ingredients and products that cannot be terminally sterilized 
may be subjected to a filtration procedure using a filter of a type that has been 
demonstrated to be satisfactory by means of a microbial challenge test using a 
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suitable test micro-organism. A suspension of Pseudomonas diminuta (ATCC 
19146, NCIMB 11091, or CIP 103020) may be suitable. Most of the ophthalmic 
solutions are sterilized by filtration method. 
Solutions are passed through a bacteria-retentive membrane with a 
nominal pore size of 0.22 µm or less or any other type of filter known to have 
equivalent properties of bacteria retention.
25  
Factors that can affect filter 
performance generally include Viscosity and surface tension of the material to be 
filtered, pH, compatibility of the material or formulation components with the 
filter itself, pressures, flow rates, maximum use time,  temperature, osmolality 
and  the effects of hydraulic shock. 
Filters are of two basic types Depth and Membrane Filter. 
Depth Filter relies on combination of tortuous pathway and adsorption to 
retain particles or micro-organisms. They are made from material such as 
diatomaceous earth, inorganic fibers, natural fibers, and porcelain. 
Membrane filters are made from cellulose ester derivatives. The 
advantages of membrane filter include no retention of product, no media 
migration, and efficiency independent flow-rate pressure differential. The major 
disadvantage of membrane filter is low capacity before clogging and need to 
prewash the filter to remove surfactant.
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 Filter Integrity Test Methods 26 
Integrity testing sterilizing filters is a fundamental requirement of critical 
process filtration applications. FDA Guidelines require integrity testing of filters 
used in the processing of sterile solutions such as large volume parenterals 
(LVPs) and small volume parenterals (SVPs). 
 
 
21 
 
 
 Classifications of integrity testing : 
1. Destructive Testing 
                Destructive bacterial challenge testing in performed in accordance with 
ASTM F838-83 methodology. Destructive challenge testing is the best way to 
determine a sterilizing filter’s ability to retain bacteria. 
  During the bacterial retention test, 0.22 µm filter discs and devices are 
challenged with a solution of culture medium containing bacteria 
(Brevundimonas diminuta ATCC 19146) at a minimum challenge of 10
7
 per cm
2
. 
The effluent is then passed through a second 0.45 µm assay filter disc that is 
placed on an agar plate and incubated. 
2. Non-Destructive Testing : 
Non-destructive testing may be done on filters before and after use. Integrity 
testing sterilizing filters before use monitors filter integrity prior to batch 
processing, preventing use of a non-integral filter. Integrity testing sterilizing 
filters after a batch has been filtered can detect if the integrity of the filter has 
been compromised during the process. 
 There are two types of non-destructive testing 
I. Bubble point test. 
II. Diffusion test. 
 
Bubble point test : 
The most widely used non-destructive integrity test is the bubble point test. 
Bubble point is based on the fact that liquid is held in the pores of the filter by 
surface tension and capillary forces. The minimum pressure required to force liquid 
out of the pores is a measure of the pore diameter. 
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  P = 4k Cosθ σ/ d 
 P = bubble point pressure                                         d = pore diameter 
k = shape correction factor                                       q = liquid-solid contact angle 
s = surface tension 
      Diffusion Test : 
 At differential gas pressures below the bubble point, gas molecules migrate 
through the water-filled pores of a wetted membrane following Ficks Law of 
Diffusion. The gas diffusional flow rate for a filter is proportional to the differential 
pressure and the total surface area of the filter. At a pressure approximately 80% of 
the minimum bubble point, the gas which diffuses through the membrane is 
measured to determine a filter’s integrity. The flow of gas is very low in small area 
filters, but it is significant in large area filters. Maximum diffusional flow 
specifications have been determined for specific membranes and devices and are 
used to predict bacterial retention test results. 
DF = K (P1-P2) A P / L 
Where: 
K = Diffusivity/Solubility coefficient        P1, P2 = Pressure difference across the       
system 
P = Membrane porosity                                      L = Effective path length 
A = Membrane area                                          DF = Diffusional Flow 
Pressure Hold Testing 
 The Pressure Hold Test, also known as pressure decay or pressure drop test, 
is a variation of the diffusion test. In this test, a highly accurate gauge is used to 
monitor upstream pressure changes due to gas diffusion through the filter. Because 
there is no need to measure gas flow downstream of the filter, any risk to 
downstream sterility is eliminated. The pressure hold value is dependent on the 
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diffusional flow and upstream volume. It can be calculated using the following 
equation: 
Pressure Hold = D (T) (Pa) / Vh = DP 
Where: 
D = Diffusion rate (cc/min)                                 T = Time (minutes) 
Pa = Atmosphere pressure (1 Atm. or 14.7 psi)  Vh = Upstream volume of apparatus 
(cc) 
DP = Pressure Drop (bar or psi) 
 
 Packaging of Finished Product 
  Ophthalmic products must possess certain levels of stability and purity in 
order to be suitable for safe and efficacious administration to patients. Ophthalmic 
products are considered stable if the active ingredient can maintain its strength at the 
level specified on the label for the maximum anticipated shelf-life under given 
environmental conditions. An ophthalmic product is considered unstable when the 
active ingredient or excipients such as preservatives, loses sufficient potency to 
adversely affect the safety or efficacy of the drug or falls outside labeled 
specifications. A typical example of relatively unstable medicinal agents is 
prostaglandin. The potency of a drug product may decline over time during storage 
due to various reasons, such as degradation of the active ingredient, reaction of the 
active ingredient with excipients or container materials, or leaching of the active 
ingredient through the container wall or absorption of the active ingredient into the 
container wall.  
In addition, many medicinal preparations contain preservatives, such as 
Chlorobutanol, Phenoxyethanol, Methyl, and Propyl parabens and Benzalkonium 
chloride, as certain concentrations, which enable storage of the medicinal 
preparations for periods of time up to 24 months or more. The preservatives may 
permeate the container wall upon storage, reducing the concentration in the 
preparation, and as a result their preservative value is diminished. Similarly, the 
purity of a medicinal preparation may also change during storage due to leaching of 
chemical or chemicals into the drug preparation from the container materials, from 
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the labels on the containers, or from the environment where the packaged 
ophthalmic product is stored. Thus, containers used for packaging medicinal 
preparations can significantly affect the stability and purity of the preparations.
27
  
 Containers commonly used for ophthalmic products include glass containers, 
and polyethylene containers. Glass containers and polyethylene containers are said 
to be superior in maintaining stability of ophthalmic preparations.
28 
  
 Glass:  
 The three types of glass recognized by USP for parenteral /ophthalmic use 
are  
a. Type I: Borosilicate glass (highly resistant)  
b. Type II: Treated soda lime glass  
c. Type III: Soda lime glass 
 Type I is borosilicate and is the least reactive as measured by a standardized 
alkalinity test run on powdered (ground) samples. Type II and III glass are soda 
lime, with type II being surface treated with sulfate, sulfite, or sulfide to make it less 
reactive. Type I glass is, theoretically, the best all purpose glass for injectables, 
ophthalmics and should be the only glass that is used with alkaline products. 
However, it is significantly more expensive than types II and III. Type II glass is 
often used for solutions that remain below pH 7.0 during their shelf life, while type 
III glass can be used for dry powders that are reconstituted. The particular glass 
container intended for use must be an integral part of product stability program. 
 Amber glass containers are often used where the product is suspected of 
being a light sensitive. The amber color is imparted by addition of iron and 
manganese oxides, the cations of which are known to catalyze the oxidative 
reactions. Studies have shown that these ions are extracted from glass and that the 
decomposition rate of several drugs, thiomerosal, amitriptylene and L-ascorbic acid 
is enhanced in amber glass containers.
29
  
 Plastic:  
 Since 1970, the use of glass containers has diminished dramatically. Plastic 
dropper bottle have been favored because they weight loss, are more resistant to 
shock and other mechanical influences, cost less and offer more design possibilities. 
Polyethylenes, that is, low density polyethylene with or without additives and 
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polypropylenes are the plastics required by the European Pharmacopoeia. Examples 
of additives for both polyethylene ad polypropylenes include antioxidants, 
stabilizers, and plasticizers, lubricants coloring matter and softening agents. 
However the United States Pharmacopoeia does not specify the types of plastic. 
 Plastic bottles are thin walled as compared to glass bottles (plastic: 0.70-1.19 
mm; glass: 2.00-2.20 mm). The wall thickness and the density of the plastic material 
determine the flexibility (ability to deform), elasticity (ability to return to its original 
form after deformation), and stiffness (resistance to deformation) of the bottle. 
Dropper bottles are shaped with round or oval bases and usually contain volume of 3 
to 15mL. 
 The disadvantage of polyethylene includes its permeability to vapors and 
gases, the adsorption and absorption of contents (e.g. preservatives like 
benzalkonium chloride and chlorobutanol). Polypropylene has poorer resistance to 
oxidation agents such as oxygen and acids which can lead to fissures and yellowing 
of plastic.
30
  
  
 Information concerning the plastic material used for the packaging purpose 
1. General information : 
 The following information should be provided for plastic materials used in 
the container, including those already described in the pharmacopoeia where the 
monographs authorize the use of several additives from which the manufacturer may 
choose one or several (within certain limits). 
– The name and grade given by the manufacturer of the material. 
– For ophthalmic and parenteral preparations, the name of the plastic manufacturer. 
– The chemical name of the material. 
– The chemical name(s) of any monomer used. 
– The complete qualitative composition of the plastic material is required where an 
interaction between the container and the contents occurs. The qualitative 
composition covers all substances, including additives such as antioxidants, 
stabilizers, catalysts, plasticizers, lubricants, solvents and/or dyes (comprising the 
color index number and/or the EC number).  
If the material has not been approved for use for packaging of food, 
toxicological data should be provided. In addition, toxicological information is 
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required for plastics normally approved for use in food packaging, if they are used 
for parenteral or ophthalmic medicinal products. 
 
2. Technical information : 
– Characteristics 
Description of the material, its solubility in various solvents. 
– Identification of the material generally by infrared absorption spectrophotometry, 
with indication of the position of characteristic absorption bands. The infrared 
spectrum of the reference material should be provided: other methods of 
identification may be appropriate. 
– Identification of the main additives in particular those which are likely to migrate 
into the contents (such as antioxidants, plasticizers, catalysts, initiators, etc.... and, 
for PVC, phthalates, adipates and organic tin compounds). 
– Identification of dyes by using chromatographic or any other appropriate method. 
– Tests 
• General tests 
• Mechanical tests 
• Physical tests: An extraction test should be performed where the plastic material is 
used as primary packaging material for liquid and semi-solid preparations. 
 The choice of solvent for this test depends on the composition of the product. 
The test should investigate the level of extractives (antioxidants, plasticizers…31) 
 There are two types of plastic containers made up of low density 
polyethylene  
1.BFS Containers 
 2. Three Piece Containers 
 BFS Containers:32 
   These types of containers are manufactured by Blow-Fill-Seal (BFS) 
technology. Blow-Fill-Seal technology is an automated packaging process whereby 
plastic containers are blow–moulded, filled, and sealed in one continuous process 
protected operation. This technology was first invented by Rommelag in the 1960s. 
Development of bottle pack range of aseptic BFS machine in the 1970s extended its 
use to pharmaceutical applications. 
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  By its very nature, the BFS process offers high level of quality assurance. By 
integrating container manufacture with product filling, BFS removes a major step 
from a production process, together with its associated risk. At the end of 2004, the 
US FDA defined for the first time regulatory requirements on the use of BFS 
technology. As a rule the filling process is considered to be a process of aseptic 
processing and is therefore subject to strict GMP requirements on these processes. 
Special attention needs to be paid some of the central requirements such as 
environmental monitoring, the absence of particles in the product and validation of 
the process by media fill. 
Ophthalmic application: 
 
  Back in the 1970s, BFS system became established in the field of eye drops 
and ocular medicines for volumes of between approximately 0.3mL to 1mL as unit 
dose presentation, and between 5 ml to 15 ml for multidose applications. The BFS 
process is particularly suited to the filling of ophthalmic solutions; most of these 
products has been are heat labile and hence will not withstand terminal sterilization. 
The sterility assurance level of BFS process is extraordinary, and has been proven by 
millions of containers manufactured in media validation runs. The system requires 
little or no human intervention during the operation cycle, and consequently the major 
source of particulate matter- the human operator- is excluded as risk of 
contamination. The regulatory authorities have recognized the immense superiority of 
containers made with BFS technology and have stated that the application advantages 
are such that the choice of aseptic production supersedes that of terminal sterilization. 
  Blow-Fill-Seal (BFS) technology is recognized as an efficient, advanced 
aseptic processing technology for ophthalmic drops. It provides far higher levels of 
quality assurance, together with definite advantages compared with traditional aseptic 
filling techniques. The technology has been well established in the field of 
ophthalmic products for long period of time, and has shown an excellent record of 
successful launches of new products and designs of benefit to patient. Worldwide 
acceptance in the ophthalmic market has confirmed the Particular suitability of this 
form of packaging for ophthalmic applications.                                 
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Fig 3: BFS Container 
 
 Three Piece Containers: 
 Three Piece Container name itself indicates system contains three 
components viz... body, nozzle, and cap. Out of which, body and nozzle are made up 
of various grades of polymers of low density polyethylene whereas caps are made 
up of high density polyethylene which results in a packaged ophthalmic products 
that is user-friendly for dispensing of the pharmaceutical preparation on a drop-by-
drop basis.  
 Cap has two rings which have to break while opening the container. Intact 
rings work as the tamper proof evidence. The nozzle is punctured with the help of 
piercing spike inside the cap.  
 Variety of grades of polymers allow manufacturer to mould the container in 
various sizes (3ml-50ml) and shapes (oval, cylindrical, quadrangular, etc). Variety 
of polymers also provides a facility for opaque (for light sensitive drugs) containers 
which give good optical and chemical resistance. Three piece containers are robust 
in nature as their wall thickness is greater than BFS containers. This limits the 
reduction in the volume of liquid by evaporation at accelerated conditions applied 
during stability testing.  
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                                         Fig 4: Three Piece Container  
Polymers used in construction of body and cap are briefly described in table 10  
Table 10: Various Polymers for Packaging Material of Ophthalmics
33
 
Sl.
No 
Parameters PE 1810 E PE 1840 H PE 3020 D PE 3040 D 3220 D 
1 Resin Type 
Polyethylene,    
low density 
Polyethylene,   
low density 
Polyethylene,   
low density 
Polyethylene,   
low density 
Polyethylene,   
low density 
2  Description 
PE 1810 E is 
LDPE with good 
flexibility and 
delivered in pellet 
form. Target 
applications are 
small blow 
moulding and 
injection 
moulding of 
engineering parts 
and tubes as well 
as domestic wares. 
PE 1840 H is a 
LDPE with a good 
flexibility and 
delivered in pellet 
form. It is 
designed for small 
blow moulding 
but also be used in 
film application 
and injection 
moulding. It can 
be used for 
medical devices 
and packaging of 
pharmaceuticals. 
PE 3020 D is 
LDPE with high 
rigidity, good 
optical and 
chemical 
resistance. It is 
delivered in pellet 
form. It can be 
used in small blow 
moulding 
including 
packaging 
pharmaceuticals 
and injection 
moulding for 
medical devices, 
closures, and 
seals. 
PE 3040 D is 
LDPE with high 
rigidity and good 
chemical 
resistance and  it 
is delivered in 
pellet form. It is 
used in small blow 
moulding 
packaging 
pharmaceuticals 
and injection 
moulding for 
medical devices, 
closures, and 
seals. 
PE 3220 D is 
LDPE with high 
rigidity and good 
chemical 
resistance and it is 
delivered in pellet 
form. It is used in 
packaging of 
pharmaceuticals in 
small blow 
moulding market. 
3 
Melt 
temperature 
170 to 220
0
 C 160 to 200
0 
C 170 to 220
0
 C 170 to 220
0
 C 170 to 220
0
 C 
4 Density 0.920 g/cm
3
 0.919 g/cm
3
 0.927 g/cm
3
 0.928 g/cm
3
 0.930 g/cm
3
 
5 
Melt Flow 
Rate 
0.40 g/10 min 
(190
0
C/2.16 
Kg) 
1.5 g/10 min 
(190
0
C/2.1
6 Kg) 
0.30 g/10 min 
(190
0
C/2.1
6 Kg) 
0.25 g/10 min 
(190
0
C/2.1
6 Kg) 
0.40 g/10 min 
(190
0
C/2.1
6 Kg) 
6 
Tensile 
Modulus 
200 Mpa 
(23
0
C) 
200 Mpa 
(23
0
C) 
300 Mpa 
(23
0
C) 
300 Mpa 
(23
0
C) 
430 Mpa 
(23
0
C) 
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 Compatibility of the packaging material with drug product:  
Chemical incompatibility may arise between the packaging materials with 
drug product due to one of the following mechanisms. 
1. Adsorption of the chemical entities onto the component surfaces. for e.g. EDTA 
and preservative like Benzalkonium chloride. 
2. More volatile preservatives like chlorobutol show rapid loss through low density 
polyethylene by adsorption and surface evaporation. 
3. Surface active ingredients which may be found in plastics may enter in to the 
product by dissolution and surface abrasion mechanisms. 
4. In case of glass, detachment of spicules may occur when alkaline solution stored 
in soda glass. 
5. Organoleptic changes may occur, caused by permission of volatile or odorous 
substances through the plastic material.
 34
   
  
 Drug products packaged in impermeable containers 
  Sensitivity to moisture or potential for solvent loss is not a concern for drug 
products packaged in impermeable containers that provide permanent barrier to 
passage of moisture or solvent. Thus, stability studies for product stored in a 
impermeable containers can be conducted under any controlled or ambient humidity 
condition. 
 
 
7 
Softening 
temperature 
92
0
C 88
0
C 102
 0
C 102
 0
C 110
 0
C 
8 
Melting 
temperature 
108
0
C 108
0
C 114
0
C 115
0
C 117
0
C 
9 Density >0.500 > 0.500 > 0.500 > 0.500 > 0.500 
10 Melt Index 
0.40g/10 min 
190
0
c/2.16 Kg 
1.5g/10  min     
190
0
c/2.16 Kg 
0.30 g/10  min     
190
0
c/2.16 Kg 
0.25g/10  min     
190
0
c/2.16 Kg 
0.40g/10  min     
190
0
c/2.16 Kg 
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 Drug products packaged in semi- permeable containers 
Aqueous –based products packaged in semi-permeable containers should be 
evaluated for potential water loss in addition to physical, chemical, biological, and 
microbiological stability.  This evaluation can be carried out under low relative 
humidity. Ultimately, it should be demonstrated that aqueous base drug product 
stored in a semi-permeable containers can withstand low relative humidity 
environment. 
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2. LITERATURE REVIEW 
1. Mitchell h. Friedlaender et al 35(2006) evaluated the effect of dilution of 
benzalkonium chloride (BAK) on the surface of human eye by determining 
its concentration in the tear film after topical administration of Gatifloxacin 
ophthalmic solution 0.3% (preserved with 0.005%benzalkonium chloride). 
The purpose of this prospective clinical study was to test the hypothesis that 
BAK would be significantly diluted shortly after topical administration and 
would thereafter have little or no effect on enhancement of the antibiotic 
efficacy of commercial Gatifloxacin on the ocular surface. Investigators 
measured concentration of tear film BAK at successive time points after 
topical administration of commercial Gatifloxacin. Results showed rapid 
BAK dilution to 6.4 µg/ml, 3.2 µg/ml, and 1.4 µg/ml, below the detection 
limit, at 30 sec, 1 min, 3min, 5 min, and 20 min after instillation of single 35 
µl drop of Gatifloxacin. Because of rapid dilution reduces the concentration 
of BAK to near zero in minute. And does not allow the time (1 hour) 
required for effective bacterial kill power. So BAK does not have significant 
effect on enhancement of antimicrobial efficacy of antibiotic on human 
ocular surface. 
2. Komei okabe et al 36(2005)  investigated the effect and safety of 
Benzalkonium chloride (BAK) on transcleral drug delivery in rabbit after 
continuous intrascleral administration. In this study, to investigate the effect 
of BAK on transcleral permeability of betamethasone 21-phosphate (BP) in 
vitro, penetration of BP aqueous solution with or without BAK across the 
rabbit sclera was evaluated using two chamber Ussing apparatus. They found 
that BAK increases concentration of BP in the vitreous and retina-choroid 
compared with the control. In the in-vitro study BAK did not increase the 
scleral permeability of BP. The result of the study demonstrates that BAK 
may improve the ocular penetration of drug in a transcleral drug delivery 
system without producing toxic reaction. 
3. M.M.A.Al-Hiti et al 37(1980) evaluated the changes in preservative 
sensitivity for the USP antimicrobial agents’ effectiveness test micro-
organisms. Investigator designed chemically defined and semi-defined media 
for preservative efficacy testing micro-organisms designated by the USP, in 
33 
 
which the organisms went into the stationary phase of growth at an optical 
density of 1.0, because of depletion of single carbon, nitrogen, or phosphate 
source. Aspergillus niger was grown on solid media containing concentration 
of these nutrients which limits the development of sporulation density. The 
ability of micro-organism to survive and grow in the presence of 
chlorhexidine, benzalkonium chloride, and thiomersal varied markedly with 
the nutrition depletion of inocula. No universal pattern of sensitivity emerged 
among micro-organisms. Only a. Niger showed little overall change in 
preservative sensitivity. These results highlight the need to define more 
adequately growth media and conditions for the production of inocula for 
antimicrobial challenge test. 
4. Roswell R. Pfister et al 38(1976) studied the effects of ophthalmic drugs, 
vehicles, and preservatives on corneal epithelium by a scanning electron 
microscope on corneal surface. Of the preparations tested 0.3 % gentamicin 
caused many central cellular microvilli to stand up prominently. Moderate 
losses of peripheral microvilli, with mild superficial cellular desquamation 
was noted with 0.25 % phospholine iodide, 2 % pilocarpine, 2 % luorescein, 
and fluor-i-strip. The top layer of epithelial cells desquamated with 4 % 
cocaine or neopolycin treatment. The top two layers of cells were lost when 
0.01 % Benzalkonium chloride was instilled. When cell death occurred 
severe membrane disruption was accompanied by loss of microvilli and 
rupture of intercellular tight junctions. These Studies show that the 
cytotoxicity of topical ocular preparations can be tested in an in vivo Model 
and evaluated by scanning electron microscopy. 
5. So-hyang Chung et.al  39(2006) studied the impact of short-term exposure of 
commercial eye drops preserved with benzalkonium chloride, a preservative 
used in many ophthalmic topical solutions, on precorneal mucin in human. 
They exposed the immortalized human corneal- limbal epithelial (HCLE) 
cells to eye drops containing BAK solutions at 0.0025% and 0.01% 
concentration for period of 15 minutes. Human corneal epithelium was 
acquired with keratectomy procedures after application of Ocuflox eye drops 
(0.3% Ofloxacin with 0.0025% BAK) for 1 week before surgery. The 
relative expression of the muc1and muc16 mucin gene was determined by 
conventional polymerase chain reaction. Human corneas exposed to 0.01% 
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BAK solutions were examined by transmission electron microscopy. The 
result showed that the expressions of muc1and muc16 were reduced after 
exposure to BAK in HCLE cells and human corneal epithelium. 
Transmission electron microscopy of the anterior corneal surface revealed 
fixation of the mucos layer after exposure to 0.01% BAK for 5 or 15 
minutes; prolong exposure (60 min) to 0.01% BAK destroys the mucos 
layer. This study demonstrates that short–term exposure  to BAK can alter 
the precorneal mucin. 
6. Michael J. Hogan (1949) reviewed that pH of the solution influence the 
stability of the formulation considerably, since Blok found a 44% 
decomposition of 0.5% Atropine solution and 89% decomposition of a 1% 
homatropine solution in one month at pH 8.3. Deterioration was less than 
20% at pH 6.8. In general, slightly acid solutions of ophthalmic drugs are 
more stable and effective. If they are too acid the free base is quite 
irritating.
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7. Luc van Santvliet et al (2004) reviewed the technical, pharmaceutical, and 
therapeutic aspects of eye drop formation and delivery. They discussed 
different types of containers and determinants of eye drop size. They 
concluded that dropper tips should deliver small-volume eye drops. The ideal 
dropper tip consist small diameter outer orifice with design clearly defining 
the surface area from which drop will fall. Surface tension reducing agents in 
formulation can reduce the drop size viscosity.
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8. Mark B. Abelson et al 42(2002) reviewed Benzalkonium background. They 
stated that BAK 0.02% and 0.01% killed 100 percent of Pseudomonas 
aeruginosa cultures and inhibited growth of Staphylococcus aureus as 
evidenced by zones of growth inhibition in agar inoculated with S. aureus.
2
 
Additionally, BAK 0.1% and 0.05% killed all strains tested of methicillin-
resistant S. aureus and methicillin-sensitive S. aureus within 20-40 seconds,
3
 
and had complete efficacy within 30 seconds in killing 100 isolates of 
Serratia marcescens, 103 of Klebsiella pneumoniae, 99 of Pseudomonas 
aeruginosa, 19 of Alcaligenes faecalis and 30 of A. xylosoxydans. 
9. Hourcade F. Sautov – Miranda V et al 43(1997) studied compatibility of 
granisetron towards glass and plastics and its stability under various storage 
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conditions.they evaluated the compatibility of graniusetron as an undiluted 
solution towards glass polypropylene and PVC containers over period of 15 
days. the solution were exposed to various temperature and light. from the 
results obtained they concluded that undiluted granisetron was stable in 
polypropylene. in contrast variations were found in concentration diluted 
granisetron with 5 % glucose and 0.9% sodium chloride. 
10. Beitz C., Bersch T. et al 44(1999) studied the compatibility of plastics with 
cytotoxic drug solutions. They compared the low density polyethylene 
(LDPE)containers with glass bottles and polyvinyl chloride (PVC). They 
concluded that investigated drugs were stable in all three containers with the 
best stability in glass bottles, followed by LDPE and PVC. 
11. Guidance for Industry (1999): “Container Closure System for Packaging of 
Human Drugs and Biologics” in 1999. The guidance notes that packaging 
should be constructed of materials that will not leach harmful or undesirable 
amount of substances to which the patient will be exposed. For ophthalmic 
drug product comprehensive assessment involves two parts: an extraction 
study of packaging components to determine which chemical species may 
migrate into dosage form and toxicological evaluation of those substances 
that are extracted to determine the safe level of exposure via label route of 
administration.
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12. Howard Schenker et al
 46
(1999) investigated the patient preference,efficacy, 
and compliance with Timolol Maleate Ophthalmic Gel-Forming Solution 
Versus Timolol Maleate Ophthalmic Solution for treating Open-Angle 
glaucoma. In this study total of 202 patients were selected and treated once 
daily with Timolol gel forming solution or twice daily with Timolol 
ophthalmic solution. This study demonstrated that patients preferred timolol 
gel once daily to timolol solution twice daily. study demonstrated more 
stinging with timolol solution and a higher percentage of blurred vision with 
timolol gel. Compliance was greater with timolol gel. This study confirms 
previous studies showing that timolol gel and timolol solution are equally 
effective in lowering IOP. The incidents of adverse drug reactions are less in 
the case of tiomol solution but however due to less dosing compliance was 
more with the Timolol gel solution. 
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13. Masayo Higashiyama et al 
47
(2003)
 
studied the Improvement of the ocular 
bioavailability of 
timolol by sorbic acid. The Timolol maleate in the presence of sorbic acid 
was tested against marketed formulations of Timolol ophthalmic solution 
(Timoptlo®), and Timolol gel forming solution (Timoptic-XE®). The 
comparison was done by various parameters like Effect of sorbic acid on the 
apparent lipophilicity of timolol, Evaluation of the effect of sorbic acid 
concentration on timolol bioavailability, Comparison of the influence of 
various timolol formulations on bioavailability, In vitro corneal penetration 
of timolol with sorbic acid. Results showed that The ocular bioavailability of 
timolol increased in sorbic acid solution due to ion pair formation. Its 
octanol/water partition coefficient also increased, suggesting the formation 
of a more lipophilic complex. The concentration of timolol in rabbit aqueous 
humor was Maximum in the presence of sorbic acid and the area under the 
curve were more than two-fold higher than those of Timoptol®, and similar 
in value to TIMOPTIC-XE®. The partition coefficient was also noted higer 
in the presence of sorbic acid. 
14. K. S. Rathore et al 48(2011) Developed an In-situ gel forming system of 
Timolol maleate by using poly acrylic acid as a gelling agent and 
hypromellose as viscolyzer. The developed formulation was therapeutically 
efficacious, non-irritant, stable and provided sustained release of the drug 
over a long period and shelf-life determined by Arrhenius equation was 1.6 
years. Intra ocular pressure determined with Schiotz tonometer and eye 
irritation. study. conducted on albino rabbits by Draize technique. The 
developed system is concluded as viable alternative for conventional 
formulations. 
15. Hyun Jung Jung et al 49(2012) fabricated a contact lenses system by 
dispersing nanoparticles of PGT (propoxylated glyceryl triacylate) that 
contain a glaucoma drug timolol. The particles were loaded into 
prefabricated lenses by soaking the lenses in a solution of particles in 
ethanol. The particle loaded gels can release timolol in phosphate buffered 
saline (PBS) for about a month at room temperature. Preliminary animal 
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studies were conducted in Beagle dogs  with lenses in which particles are 
loaded by soaking the lenses in ethanol show a reduction in IOP. 
16. Pfister et al 50(1976) found that BAK-containing preparations can cause 
severe plasma membrane disruptions and cell death in the cornea. Pfister et 
al. used scanning electron microscopy (SEM) to study the effect of topical 
drugs, vehicles, and preservatives (i.e. BAK) on the surface corneal 
epithelium. Treatment of the cornea with a 0.01 percent solution of BAK 
resulted in the top two layers of cells being desquamated. When cell death 
occurred, severe membrane disruption was accompanied by loss of microvilli 
and rupture of intercellular tight junctions. They concluded that frequent use 
of BAK-containing preparations can act as an iatrogenic impediment to the 
epithelial healing process and can shorten the tear film break up time. 
17. Burstein et al 51(1977) studied the effects of very low concentrations of 
preservatives (e.g. BAK, thimerosal and amphotericin B) on the cornea. 
Burstein et al. found that BAK, at a concentration as low as 0.01%, briefly 
increased ion transport, and then greatly decreased epithelial resistance with 
severe disruption of surface cell layers occurring simultaneously with the 
decrease in resistance. Burstein, found BAK causes a progressive increase in 
damage to corneal epithelial cells at concentrations between 0.001% and 
0.01%, as determined by SEM. 
18. Solomun L et al  52(2008) investigated the impact of primary packaging 
material on the quality of parenteral products.they used the dual chamber 
vials made up of Type I borosilicate glass. they evaluated the compatibility 
of solutrion with glass container in view of pH shift.on the basis of results 
obtained they concluded that pH value of the reconstituted solution remains 
unchanged in samples tested both ex-tempore and and after in-use period of 
48 hours. 
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3. AIM AND OBJECTIVES 
 Recently, ophthalmic drug delivery has become the standards in the modern 
pharmaceutical design and intensive research for achieving better drug product 
effectiveness, reliability, and safety. Topical medication to eye through eye drops 
will continue to account for the largest share (up to 90%) of drug delivery systems.
 
The ophthalmic solution with minimum concentration of preservative preparation in 
an appropriate packaging material appears to be most attractive approach for the 
process development and scale-up point of view. 
 
 A first generation Beta blocker has found its applicability in treating Chronic 
Open angled Glaucoma and used widely in young as well as adults, commonly 
associated with multiple doses. 
 Ophthalmic medication stored in multiple dose containers is required by the 
U.S. Food and Drug Administration to contain a preservative so that patients are 
provided with microbe free medication. Benzalkonium chloride in concentrations 
from 0.1% to 0.0001% induced dose-dependent growth arrest and conjunctival 
epithelial cell death, either delayed or immediately after administration. In such 
case, a preservative Benzalkonium chloride must be used within reasonable bound. 
Benzalkonium chloride can provide more help than harm. 
Therefore, the aim of the present study was to formulate a formulation for 
Timolol Maleate (0.5%) ophthalmic solution using different concentration of 
Benzalkonium chloride as preservative. While reducing the concentration of 
Benzalkonium chloride it must be keep in mind that added quantity of preservative 
must meet compendial requirement of Preservative Efficacy Testing.  
 The present research work is also planned to provide the data about the 
selection of suitable primary packaging material for Timolol Maleate (0.5%) 
ophthalmic solution to achieve the better stability during the shelf life of the product. 
As there are several factors responsible for the incompatibility of packaging material 
with the product, most suitable packaging material must be selected. 
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 The product will be evaluated for stability, potency, toxicity, and safety 
under the accelerated conditions of temperature and humidity. 
 
 OBJECTIVES  
              The following objectives were thus framed for the present investigation 
1. The designed optimized formulation with minimum concentration of 
Benzalkonium chloride will provide better therapeutic effect without the corneal 
irritation caused due the deposition of Benzalkonium chloride. 
2. The optimized formulation with minimum concentration of Benzalkonium 
chloride, will meet the compendial requirement of preservative efficacy test, so 
that it will maintain the sterility of the product throughout the shelf life of product. 
3. Effective antimicrobial activity without interference with the mechanism of action 
of the active ingredient. 
4. As there will be no eye irritation and conjunctival epithelial cell death, optimized 
formulation will help to achieve the better patient compliance and improved 
therapeutics with reduced systemic side effects and toxicity in ocular bacterial 
infection. 
5. The selected packaging material will provide the better stability at both room and 
elevated conditions of temperature and humidity. 
6. No or minimum introduction of extractables and leachables in the product from 
the packaging material. 
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4. PLAN OF WORK 
The present proposed research work was planned as per the following 
experimental protocol – 
 
 Phase I Study 
Step 1.  Literature Survey; the various work carried out on this topic is 
reviewed. 
Step 2. Procurement of drug, preservative, other ingredients and various 
types of containers required for the study. 
Step 3. Physical characterization of drug sample includes description, 
identification, solubility, loss on drying, and assay by 
potentiometric titration. 
 
 Phase II Study 
   Step 4.    Development strategy 
 
  Step 4.1  Prototype formulation development: the excipients will  
scientifically identify based on their category 
  Step 4.2  Optimization of formula and process 
  Step 4.3  Development of manufacturing process 
  Step 4.4  Determination of Preservative Efficacy by microbial plate count 
method. 
  Step 4.5  Product analysis 
  Step 4.5.1  In Process Tests: pH, Leak test and Visual inspection for 
particulate matter. 
  Step 4.5.2  Finished product analysis: Appearance, assay, Osmolality and 
pH  
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 Phase III Study 
Step 4.6     Stability and Container compatibility study. 
 
Step 4.6.1 Charging of optimized batch in various packaging containers viz.. 
glass and plastic containers to stress condition of temperature 
and accelerated condition of temperature and humidity 
Step 4.6.2 Analysis of product at every station of the stability: Appearance, 
Assay of active drug and preservative, Osmolality, pH, Drop 
size study, and Water loss study (for semi permeable containers 
only). 
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5.1.  DRUG PROFILE 
 
            Drug used for the study is from Anti-hypertensive β- blocker category. 
Details of Timolol maleate are given are as follows. 
 
 Molecular Structure : 
 
 
 
Fig 5: Molecular structure of Timolol 
2-Propanol, 1-[(1,1-dimethylethyl)amino]-3-[[4-(4-morpholinyl)-1,2,5-thiadiazol-3-
yl]oxy]-, (S)-, (Z)-2-butenedioate (1:1) (salt). 
 
 Monograph53 : 
 
                      Molecular weight             : 432.50 
                      Molecular formula           : C13H24N4O3S • C4H4O4 
          Description                       : It is a white, odorless, crystalline powder.     
                      Solubility                          : Soluble in water, methanol, and alcohol. 
                      Category     :  β- adrenergic blocking agent.. 
                Storage                            : Store in well-closed, light resistant    
                                                           container.  
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 Therapeutic uses54 : 
 
  Treatment of hypertension, alone or in combination with other agents; 
reduction of risk of reinfarction post-MI; migraine prophylaxis; treatment of 
elevated IOP in chronic open-angle glaucoma, ocular hypertension, aphakic 
glaucoma patients, patients with secondary glaucoma, and in patients with elevated 
Intra Ocular Pressure(IOP) who need ocular pressure lowering. 
 
 Pharmacology : 
 
 Timolol maleate is a β1 and β2 (non-selective) adrenergic receptor blocking 
agent that does not have significant intrinsic sympathomimetic, direct myocardial 
depressant, or local anesthetic (membrane-stabilizing) activity. 
            β -adrenergic receptor blockade reduces cardiac output in both healthy 
subjects and patients with heart disease. In patients with severe impairment of 
myocardial function, beta-adrenergic receptor blockade may inhibit the stimulatory 
effect of the sympathetic nervous system necessary to maintain adequate cardiac 
function. 
           β -adrenergic receptor blockade in the bronchi and bronchioles results in 
increased airway resistance from unopposed parasympathetic activity. Such an effect 
in patients with asthma or other bronchospastic conditions is potentially dangerous. 
           Timolol maleate ophthalmic solution, when applied topically on the eye, has 
the action of reducing elevated as well as normal intraocular pressure, whether or 
not accompanied by glaucoma. Elevated intraocular pressure is a major risk factor in 
the pathogenesis of glaucomatous visual field loss. The higher the level of 
intraocular pressure, the greater the likelihood of glaucomatous visual field loss and 
optic nerve damage. 
          The onset of reduction in intraocular pressure following administration of 
timolol maleate ophthalmic solution can usually be detected within one-half hour 
after a single dose. The maximum effect usually occurs in one to two hours and 
significant lowering of intraocular pressure can be maintained for periods as long as 
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24 hours with a single dose. Repeated observations over a period of one year 
indicate that the intraocular pressure-lowering effect of timolol is well maintained. 
          The precise mechanism of the ocular hypotensive action of timolol is not 
clearly established at this time. Tonography and fluorophotometry studies in man 
suggest that its predominant action may be related to reduced aqueous formation. 
However, in some studies a slight increase in outflow facility was also observed. 
  
 Pharmacokinetics of drug :  
Absorption : 
Timolol is rapidly and about 90% absorbed following oral administration. T max is 
approximately 1 to 2 hrs. 
Distribution : 
Timolol is not extensively bound to plasma proteins. 
Metabolism : 
Timolol undergoes approximately 50% first-pass metabolism. 
Elimination : 
Timolol t ½ is approximately 4 hrs. 
              In a study of plasma drug concentration in six subjects, the systemic 
exposure to timolol was determined following twice daily administration of timolol 
maleate ophthalmic solution, 0.5%. The mean peak plasma concentration following 
morning dosing was 0.46 ng/mL and following afternoon dosing was 0.35 ng/mL. 
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 Adverse reactions : 
    Timolol maleate has good safety records. As with many topically applied 
ophthalmic drugs, this drug also absorbed systemically. The Adverse reactions 
generally produced 
Gastro Intestinal :  Abdominal pain, nausia, diarrhea. 
CNS                    : Dizziness, depression, lethargy, headach, insomnia. 
Respiratory          : Wheezing, cough, breathing difficulties in asthmatic 
patients 
Metabolic            : Alteration of glucose metabolism, increased uric acid. 
Micellaneous       : joint pains, muscle cramps. 
 
         Timolol is contraindicated in the patients with  
 Bronchial asthma 
 History of bronchial asthma 
 Severe chronic obstructive pulmonary disease 
 Sinus bradycardia 
 Antiventricular blockade 
 Cardiogenic shock 
 Hypersensitivity to the product. 
 Dosage forms : 
1. Topical ophthalmic solutions  : 0.25%, 0.5% 
2. Tablets                                     : 5mg, 10mg, 20mg 
3. Intravenous injections             : 0.5% 
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5.2. EXCIPIENTS REVIEW 
              The various excipients used in the Formulation are Benzalkonium chloride, 
Dibasic Sodium Phosphate, Monobasic Sodium phosphate, Sodium Hydroxide. 
I. BENZALKONIUM CHLORIDE 
55
 
 Nonproprietary Names : 
 BP: Benzalkonium chloride 
 JP: Benzalkonium chloride 
 PhEur: Benzalkonii chloridum 
 USPNF: Benzalkonium chloride 
 Synonyms : 
       Alkyl benzyl dimethyl ammonium chloride; alkyl dimethyl benzyl 
ammonium chloride; BKC; Hyamine 3500; Pentonium; Zephiran. 
 Chemical Name and CAS Registry Number : 
Alkyl dimethyl (phenyl methyl) ammonium chloride [8001-54-5] 
 Empirical Formula : 
                                                     [C6H5CH2N(CH3)2R]Cl. 
 Molecular Weight :        360. 
 Structural formula : 
 
R = mixture of alkyls: n-C8H17 to n-C18H37; mainly n-C12H25 (dodecyl), n-C14H29 
(tetradecyl), and n-C16H33 (hexadecyl). 
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 Functional Category : 
Antimicrobial preservative; antiseptic; disinfectant; solubilizing agent; 
wetting agent. 
 Applications in Pharmaceutical Formulation or Technology 
Benzalkonium chloride is a quaternary ammonium compound used in 
pharmaceutical formulations as an antimicrobial preservative. In ophthalmic 
preparations, benzalkonium chloride is one of the most widely used preservatives 
(0.01–0.02% w/v) Often it is used in combination with other preservatives or 
excipients, particularly 0.1% w/v disodium edetate, to enhance its antimicrobial 
activity against strains of Pseudomonas. 
            Benzalkonium chloride (0.002–0.02% w/v) in nasal and otic formulations, 
(0.01% w/v) small-volume parenteral products and cosmetics is used.  
 Description : 
        Benzalkonium chloride occurs as a white or yellowish-white amorphous 
powder, a thick gel, or gelatinous flakes. It is hygroscopic, soapy to the touch, and 
has a mild aromatic odor and very bitter taste.  
 
 Typical Properties 
 Antimicrobial activity : 
                   Benzalkonium chloride solutions are active against a wide range of 
bacteria, yeasts, and fungi. Activity is more marked against Gram-positive than 
Gram-negative bacteria. The antimicrobial activity of benzalkonium chloride is 
significantly dependent upon the alkyl composition of the homolog mixture. 
However, combined with disodium edetate (0.01–0.1% w/v), the activity against 
Pseudomonas aeruginosa is increased. Inhibitory activity increases with pH, 
although antimicrobial activity occurs at pH 4–10.      
 Acidity/alkalinity: pH = 5–8 for a 10% w/v aqueous solution. 
 Density: ≈0.98 g/cm3 at 20°C 
 Melting point: ≈40°C 
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 Partition coefficients:  
             The octanol : water partition coefficient varies with the alkyl chain length 
of the homolog; 9.98 for C12, 32.9 for C14, and 82.5 for C16. 
 Solubility:  
             Practically insoluble in ether; very soluble in acetone, ethanol (95%), 
methanol, propanol, and water. Aqueous solutions of benzalkonium chloride foam 
when shaken. 
 Stability and Storage Conditions : 
                 Benzalkonium chloride is hygroscopic and may be affected by light, air, 
and metals. 
 Incompatibilities : 
                 Incompatible with aluminum, anionic surfactants, some rubber mixes, and 
some plastic mixes. Benzalkonium chloride has been shown to be adsorbed to 
various filtering membranes, especially those that are hydrophobic or anionic. 
 
 Safety : 
                Benzalkonium chloride is usually nonirritating, nonsensitizing, and is well 
tolerated in the dilutions normally employed on the skin and mucous membranes. 
However, benzalkonium chloride has been associated with adverse effects when 
used in some pharmaceutical formulations. Ototoxicity can occur when 
benzalkonium chloride is applied to the ear and prolonged contact with the skin can 
occasionally cause irritation and hypersensitivity. Benzalkonium chloride is also 
known to cause bronchoconstriction in some asthmatics when used in nebulizer 
solutions. 
                Toxicity experiments with rabbits have shown benzalkonium chloride to 
be harmful to the eye in concentrations higher than that normally used as a 
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preservative. However, the human eye appears to be less affected than the rabbit eye 
and many ophthalmic products 
have been formulated with benzalkonium chloride 0.01% w/v as the preservative. 
 
 Regulatory Status : 
              Included in the FDA Inactive Ingredients Guide (inhalations, IM 
injections, nasal, ophthalmic, otic, and topical preparations). Included in 
nonparenteral medicines licensed in the UK. It is also included in the Canadian 
List of Acceptable Non-medicinal Ingredients. 
II. DIBASIC SODIUM PHOSPHATE
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 Nonproprietary Names : 
 BP:      Anhydrous Disodium Hydrogen Phosphate 
            Disodium Hydrogen Phosphate Dihydrate 
            Disodium Hydrogen Phosphate Dodecahydrate 
 JP:       Dibasic Sodium Phosphate Hydrate 
 PhEur: Disodium Phosphate, Anhydrous 
            Disodium Phosphate Dihydrate 
            Disodium Phosphate Dodecahydrate 
 USP:   Dibasic Sodium Phosphate 
 
 Synonyms : 
             Dinatrii phosphas anhydricus; dinatrii phosphas dihydricus; dinatrii 
phosphas dodecahydricus; disodium hydrogen phosphate; disodium 
phosphate; E339; phosphoric acid, disodium salt; secondary sodium 
phosphate; sodium orthophosphate. 
 Chemical Name and CAS Registry Number : 
                        Anhydrous dibasic sodium phosphate [7558-79-4] 
                        Dibasic sodium phosphate dihydrate [10028-24-7] 
                        Dibasic sodium phosphate dodecahydrate [10039-32-4] 
                        Dibasic sodium phosphate heptahydrate [7782-85-6] 
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                        Dibasic sodium phosphate hydrate [10140-65-5] 
                        Dibasic sodium phosphate monohydrate [118830-14-1] 
 
 Empirical Formula and Molecular Weight : 
                    Na2HPO4                141.96 (for Anhydrate) 
                    Na2HPO4_H2O      159.94 (for Monohydrate) 
                    Na2HPO4_2H2O    177.98 (for Dihydrate) 
                    Na2HPO4_7H2O    268.03 (for Heptahydrate) 
                    Na2HPO4_12H2O  358.08 (for Dodecahydrate)  
 Functional Category : 
       Buffering agent; sequestering agent. 
 Applications in Pharmaceutical Formulation or Technology 
                  Dibasic sodium phosphate is used in a wide variety of pharmaceutical 
formulations as a buffering agent and as a sequestering agent. Therapeutically, 
dibasic sodium phosphate is used as a mild laxative and in the treatment of 
hypophosphatemia. Dibasic sodium phosphate is also used in food products; for 
example as an emulsifier in processed cheese. 
 Description : 
The USP 32 states that dibasic sodium phosphate is dried or contains, 1, 
2, 7, or 12 molecules of water of hydration. 
                  Anhydrous dibasic sodium phosphate occurs as a white powder. The 
dihydrate occurs as white or almost white, odorless crystals. The heptahydrate 
occurs as colorless crystals or as a white granular or caked salt that effloresces in 
warm, dry air. The dodecahydrate occurs as strongly efflorescent, colorless or 
transparent crystals. 
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 Typical Properties 
Table 11: Typical Properties of Dibasic Sodium phosphate 
Acidity/alkalinity 
pH = 9.1 for a 1% w/v aqueous solution of the anhydrous 
material at 258°C. A saturated aqueous solution of the 
dodecahydrate has a pH of about 9.5 
Ionization 
constants 
PKa1 = 2.15 at 258°C; 
pKa2 = 7.20 at 258°C; 
pKa3 = 12.38 at 258°C. 
Moisture content 
The anhydrous form is hygroscopic and will absorb up to 7 
moles of water on exposure to air, whereas the heptahydrate is 
stable in air. 
Solubility 
Very soluble in water, more so in hot or boiling water; 
practically insoluble in ethanol (95%). The anhydrous material 
is soluble 1 in 8 parts of water, the heptahydrate 1 in 4 parts of 
water, and the dodecahydrate 1 in 3 parts of water 
Osmolarity 
A 2.23% w/v aqueous solution of the dihydrate is isoosmotic 
with serum; a 4.45% w/v aqueous solution of the 
dodecahydrate is isoosmotic with serum. 
 
 Stability and Storage Conditions : 
                 The anhydrous form of dibasic sodium phosphate is hygroscopic. When 
heated to 408°C, the dodecahydrate fuses; at 1008°C it loses its water of 
crystallization; and at a dull-red heat (about 2408°C) it is converted into the 
pyrophosphate, Na4P2O7. Aqueous solutions of dibasic sodium phosphate are stable 
and may be sterilized by autoclaving. The bulk material should be stored in an 
airtight container, in a cool, dry place. 
 
 Incompatibilities : 
                 Dibasic sodium phosphate is incompatible with alkaloids, antipyrine, 
chloral hydrate, lead acetate, pyrogallol, resorcinol and calcium gluconate, and 
ciprofloxacin. Interaction between calcium and phosphate, leading to the formation 
of insoluble calcium–phosphate precipitates, is possible in parenteral admixtures. 
52 
 
 Safety : 
               Dibasic sodium phosphate is widely used as an excipient in parenteral, 
oral, and topical pharmaceutical formulations. Phosphate occurs extensively in the 
body and is involved in many physiological processes since it is the principal anion 
of intracellular fluid. Excessive administration through oral route may cause some 
side effects like Diarrhea, nausea and vomiting etc,.. But the level of Dibasic sodium 
phosphate used in the pharmaceutical formulations is not usually produse side 
effects. 
 Regulatory Status : 
             GRAS listed. Accepted in Europe for use as a food additive. Included in the 
FDA Inactive Ingredients Database (injections; infusions; nasal, ophthalmic, oral, 
otic, topical, and vaginal preparations). Included in nonparenteral and parenteral 
medicines licensed in the UK. Included in the Canadian List of Acceptable Non-
medicinal Ingredients. 
 
III. MONOBASIC SODIUM PHOSPHATE
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 Nonproprietary Names : 
 BP:      Anhydrous Sodium Dihydrogen Phosphate 
            Sodium Dihydrogen Phosphate Monohydrate 
            Sodium Dihydrogen Phosphate Dihydrate 
 PhEur: Sodium Dihydrogen Phosphate Dihydrate 
 USP:   Monobasic Sodium Phosphate 
 
 Synonyms : 
          Acid sodium phosphate; E339; Kalipol 32; monosodium orthophosphate; 
monosodium phosphate; natrii dihydrogenophosphas dihydricus; phosphoric acid, 
monosodium salt; primary sodium phosphate; sodium biphosphate; sodium 
dihydrogen orthophosphate; sodium dihydrogen phosphate. 
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 Chemical Name and CAS Registry Number : 
                 Anhydrous monobasic sodium phosphate [7558-80-7] 
                 Monobasic sodium phosphate monohydrate [10049-21-5] 
                 Monobasic sodium phosphate dihydrate [13472-35-0] 
 
 Empirical Formula and Molecular Weight : 
                    NaH2PO4                119.98 (for Anhydrate) 
                    NaH2PO4_H2O      137.99 (for Monohydrate) 
                    NaH2PO4_2H2O    156.01 (for Dihydrate) 
 
 Functional Category : 
       Buffering agent; sequestering agent; emulsifying agent 
 Applications in Pharmaceutical Formulation or Technology 
             Monobasic sodium phosphate is used in a wide variety of pharmaceutical 
formulations as a buffering agent and as a sequestering agent. Therapeutically, 
monobasic sodium phosphate is used as a mild saline laxative and in the treatment of 
hypophosphatemia.                 
 Monobasic sodium phosphate is also used in food products, for example, in 
baking powders, and as a dry acidulant and sequestrant. 
 
 Description : 
            The USP 32 states that monobasic sodium phosphate contains one or two 
molecules of water of hydration or is anhydrous. 
            The hydrated forms of monobasic sodium phosphate occur as odorless, 
colorless or white, slightly deliquescent crystals. The anhydrous form occurs as a 
white crystalline powder or granules. 
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Table 12: Typical Properties of Monobasic Sodium phosphate 
Acidity/alkalinity pH = 4.1–4.5 for a 5% w/v aqueous solution of the 
monohydrate at 258°C. 
Density 1.915 g/cm3 for the dihydrate. 
Dissociation 
constant 
pKa = 2.15 at 258°C 
Solubility Soluble 1 in 1 of water; very slightly soluble in 
ethanol(95%). 
 
 Stability and Storage Conditions : 
             Monobasic sodium phosphate is chemically stable, although it is slightly 
deliquescent. On heating at 1008°C, the dihydrate loses all of its water of 
crystallization. On further heating, it melts with decomposition at 2058°C, forming 
sodium hydrogen pyrophosphate, Na2H2P2O7. At 2508°C it leaves a final residue of 
sodium metaphosphate, NaPO3. 
              Aqueous solutions are stable and may be sterilized by autoclaving. 
Monobasic sodium phosphate should be stored in an airtight container in a cool, dry 
place. 
 Incompatibilities : 
             Monobasic sodium phosphate is an acid salt and is therefore generally 
incompatible with alkaline materials and carbonates; aqueous solutions of 
monobasic sodium phosphate are acidic and will cause carbonates to effervesce. 
             Monobasic sodium phosphate should not be administered concomitantly 
with aluminum, calcium, or magnesium salts since they bind phosphate and could 
impair its absorption from the gastrointestinal tract. Interaction between calcium 
and phosphate, leading to the formation of insoluble calcium phosphate precipitates, 
is possible in parenteral admixtures. 
 Regulatory Status : 
 GRAS listed. Included in the FDA Inactive Ingredients Guide (inhalations; 
injections; ophthalmic preparations; oral capsules, solutions, suspensions, syrups, 
and tablets; rectal topical, and vaginal preparations). Included in nonparenteral and 
parenteral medicines licensed in the UK. Included in the Canadian List of 
Acceptable Non-medicinal Ingredients. 
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IV. SODIUM HYDROXIDE
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 Nonproprietary Names : 
 BP: Sodium hydroxide 
 JP: Sodium hydroxide 
 PhEur: Natrii hydroxidum 
 USPNF: Sodium hydroxide 
 Synonyms : 
            Caustic soda; E524; lye; soda lye; sodium hydrate. 
 Chemical Name and CAS Registry Number:  
            Sodium hydroxide [1310-73-2] 
 Empirical Formula and Molecular Weight:  NaOH; 40.00 
 Structural Formula: NaOH 
 Functional Category : Alkalizing agent; buffering agent. 
 Applications in Pharmaceutical Formulation or Technology 
            Sodium hydroxide is widely used in pharmaceutical formulations to adjust 
the pH of solutions. It can also be used to react with weak acids to form salts. 
 Description : 
 Sodium hydroxide occurs as a white or nearly white fused mass. It is 
available in small pellets.Sodium hydroxide is very deliquescent and on exposure to 
air it rapidly absorbs carbon dioxide and water. 
 
 Typical Properties : 
 Acidity/alkalinity: 
pH ≈ 12 (0.05% w/w aqueous solution); 
pH ≈ 13 (0.5% w/w aqueous solution); 
pH ≈ 14 (5% w/w aqueous solution). 
 Melting point: 318°C 
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 Solubility: Solubility of the sodium hydroxide in various solvents is 
given the Table 13. 
 
Table 13: Solubility of Sodium hydroxide. 
Solvent Solubility at 20°C  
Ethanol 1 in 7.2 
Ether Practically insoluble 
Glycerin Soluble 
Methanol 1 in 4.2 
Water 1 in 0.9 
 
 
 Stability and Storage Conditions : 
 Sodium hydroxide should be stored in an airtight nonmetallic container in a 
cool, dry place. When exposed to air, sodium hydroxide rapidly absorbs moisture 
and liquefies. 
 Incompatibilities : 
            Sodium hydroxide is a strong base and is incompatible with any compound 
that readily undergoes hydrolysis or oxidation.  
 Regulatory Status : 
           GRAS listed. Accepted for use as a food additive in Europe. Included in the 
FDA Inactive Ingredients Guide (dental preparations; injections; inhalations; nasal, 
ophthalmic, oral, otic, rectal, topical, and vaginal preparations). Included in 
nonparenteral and parenteral medicines licensed in the UK. Included in the Canadian 
List of Acceptable Non-medicinal Ingredients. 
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6.1. MATERIAL AND INSTRUMENTS 
Drug, excipients and material used in the experiment are listed in Table 14  
Table 14: List of Material used 
S. No. Name of Material Manufacturer 
1 Timolol Maleate USP Syn-tech pharma , Taiwan 
2 
Benzalkonium 
chloride USP 
Merck Ltd. Germany 
3 
Dibasic Sodium 
phosphate USP 
Merck Ltd. Germany 
4 
Monobasic Sodium 
Phosphate USP 
Merck Ltd. Germany 
5 
Sodium hydroxide 
USP 
Merck Ltd. Germany 
6 Water for Injection In House 
7 Growth Media High Media, Mumbai 
8 Neutralizer media High Media, Mumbai 
9 
Three piece 
containers 
Rexam Packagings, Bangalore 
10 BFS containers Borealis Pvt ltd, Mumbai 
11 Glass containers Matri Mirra, Hyderabad 
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Instruments and equipments used in experimental work are listed in Table 15. 
Table 15: List of Instruments used 
S. no. Instrument Manufacturer 
1 Digital Potentiometer Meter Toledo DL-50, USA 
2 Digital Polarimeter 
Rudolph Research Analytical 
Autopol

IV, USA 
3 UV- Spectrophotometer 1800,Pharmaspec, Shimadzu,Japan 
4 Balance CPA224S, Sartorius, Bangalore 
5 Magnetic stirrer Remi equipments, Bangalore 
6 pH meter Cyberscan

510
PC
 Eutech, Japan 
7 Osmometer 
Model-3320, Advanced 
instruments INC, USA 
8 PVDF Filter Sartorius, Bangalore 
9 
Laminar flow clean air 
station 
Model no. 1500C-48-24-24 Klenz 
Pvt.Ltd, Mumbai 
10 Digital colony counter 
Servewell instruments, Pvt. Ltd, 
Bangalore 
11 HPLC 
Shimadzu Prominence LC-2010 
CHT model, Japan 
12 Stability chambers 
Newtronics company Pvt.Ltd. 
Mumbai 
13 Hot air oven Alpha scientific, Bangalore 
14 Incubator Servewell instruments, Pvt. Ltd, 
Bangalore 
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6.2. EXPERIMENTAL WORK 
 PREFORMULATION STUDIES59    
The Preformulation studies like Physical characterization and Analytical 
characterization of drug sample including description, identification, melting 
point, solubility, loss on drying, and assay by potentiometric titration method were 
performed. 
 
 PHYSICAL CHARACTERIZATION OF DRUG SAMPLE    
Timolol Maleate was supplied by Syn-tech pharma, Taiwan and was 
characterized for its identification and authenticity.  
            The drug was physically characterized according to following methods-    
1. Description : 
            The received sample Timolol Maleate was subjected to the following tests 
for its characterization: 
 Nature of drug sample  
            The drug sample was observed visually and viewed under the Compound 
microscope for the determination of its nature and then the results were compared 
with the official books and British Pharmacopoeia and Ph Eur 2006. 
 Color of drug sample 
            The drug sample was viewed visually for the determination of its color and 
then the results were compared with the British Pharmacopoeia and Ph Eur 2006         
2. Loss on drying : 
 Loss on drying was performed for the sample of Timolol maleate according 
to method specified in British Pharmacopoeia and Ph Eur. It was determined on 
1.000 g of Timolol sample by drying at 100
0
C-105
0
C for 4 hours. The results were 
then compared with those given in the official books and British Pharmacopoeia and 
Ph Eur 2006. 
 
3. Solubility: 
 The solubility of the Timolol maleate sample was carried out in different 
aqueous and organic solvents like water, glacial acetic acid, methylene chloride, 
Chloroform and methanol according to British Pharmacopoeia. The results were 
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then compared with those given in the official books and British Pharmacopoeia and 
Ph Eur 2006  
 
 ANALYTICAL CHARACTERIZATION OF DRUG SAMPLE59    
1. Absorbance:   
         Dissolve 0.5 g of Timolol maleate in 0.12 N Hydrochloric acid and dilute to 
25  L with the same solvent.  The absorbance of the solution measured at 294 nm, 
is not greater than 0.3 on dried basis.   
2. Optical Rotation:   
         Dissolve 50 mg per ml in 0.1 N Hydrochloric acid. The angle of optical 
rotation must be  between -11.7
0
 and -12.5
0 
 ( λ= 405 nm). 
3. Assay:  
         Assay was performed using digital potentiometer. About 800 mg of Timolol 
maleate was accurately weighed, and was transferred to 400-mL beaker, 90 ml of 
Glacial acetic anhydride was added, and stirred to dissolve. Titration was 
performed with 0.1 N Perchloric acid. The end point was determined 
potentiometrically, using a glass silver electrode system. The first two inflection 
points were used. A blank determination was performed. Each ml of perchloric 
acid is equivalent to 43.25 mg of C13H24N4O3S. C4H4O4 
.            
 FORMULATION STUDIES 
 Development Strategy :  
            Development of Timolol Maleate ophthalmic solution is divided in to two 
phases as follows. 
1. Prototype Formulation Development :  
           The following excipients were scientifically identified based on their 
functional. The rational for selecting the excipients is given below. 
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Table 16: Prototype Formulation 
S. 
No. 
Name of the 
Excipients 
Category Uses 
1. 
Benzalkonium 
chloride 
Preservative 
Benzalkonium chloride prevents 
bacterial and fungal contamination 
of the product during its shelf life. 
2. 
Dibasic Sodium 
Phosphate 
Buffering agent, 
Sequestering 
agent 
Buffering agent and electrolyte 
replenisher, when combined with 
other phosphates 
3 
Monobasic 
Sodium 
Phosphate 
Buffering agent, 
Sequestering 
agent, 
Emulsifying agent 
Buffering agent and electrolyte 
replenisher, when combined with 
other phosphates 
4 Sodium hydroxide Alkali For pH adjustment 
 
2. Process Development  
 
 
Fig 6: Manufacturing Process Flow Chart 
 
 
 
 
DISPENCING 
Solubilization 
of Phosphates 
Addition of BKC  
to Buffer 
Solubilization 
of  Timolol 
Maleate 
pH adjustment 
to 6.8-7.0 
Filteration 
using 0.22μ 
filter 
Filling in Sterile 
Class100 area 
Labelling and 
packing 
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3. Manufacturing Process : 
 
1.  Dibasic Sodium Phosphate and Monobasic Sodium Phosphate were dissolved in 
water for injection by the slow addition. pH was adjusted to the 6.8-7.0 using 5% 
sodium hydroxide. 
2.  To this container with buffer solution of phosphates, Benzalkonium chloride was 
added with continuous stirring.  
3. After solubilizing the excipients, to this solution the Timolol maleate USP was 
added and mixed vigorously until it dissolved in the solution.  
4.  The solution pH was adjusted to the 6.8-7.0 using 5% Sodium hydroxide 
solution. 
5. The volume was made with water for injection. 
6. Bulk Timolol maleate solution was filtered through 0.22 µ PVDF sterilizing grade 
filter. 
7. Solution was filled into two types of LDPE containers and glass containers in 
sterile area (Class 100) under Laminar Air Flow. LDPE containers were pre-
sterilized with gamma radiation. Glass containers were washed with filtered water 
for injection and were sterilized by Dry Heat Sterilization (160°C for 2 hours).  
8. Both filled LDPE and Glass vials were inspected individually against black and 
white surface for particulate matter.  
Above procedure was followed for all the six batches each of 500 ml. 
 
4. FORMULATION DESIGN  
 The proposed formula was optimized by varying the concentration of 
Benzalkonium chloride. The quantities of Timolol maleate and other excipients were 
kept constant. As the aim of the present study was to optimize the concentration of 
BKC in formulation for Timolol maleate (0.5%) ophthalmic solution.  
            Batches were planned by taking different concentrations viz.0.0 % v/v,  
0.01%,0.012%, 0.016%, and 0.02% ,0.024 % v/v of BKC, Timolol maleate 0.5%, 
Dibasic Sodium Phosphate, Monobasic Sodium Phosphate and Sodium hydroxide to 
adjust pH between 6.8 and 7.0 and volume was made up by water for injection. 
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Table 17: Composition of Timolol Maleate Ophthalmic Solution. 
 
Name of 
ingredients 
Formulation Batches 
OPT/TIM/  
T-001 
OPT/TIM/ 
T-002 
OPT/TIM/ 
T-003 
OPT/TIM/ 
T-004 
OPT/TIM/ 
T-005 
OPT/TIM/ 
T-006 
Timolol 
maleate 
6.8 mg/ml 6.8 mg/ml 6.8 mg/ml 6.8 mg/ml 6.8 mg/ml 6.8 mg/ml 
Benzalkonium 
chloride* 
0.0%v/v 0.01%v/v 
0.012% 
v/v 
0.016% 
v/v 
0.02% v/v 
0.024% 
v/v 
Dibasic 
Sodium 
Phosphate 
30.42 
mg/ml 
30.42 
mg/ml 
30.42 
mg/ml 
30.42 
mg/ml 
30.42 
mg/ml 
30.42 
mg/ml 
Monobasic 
Sodium 
Phosphate 
6.10 
mg/ml 
6.10 
mg/ml 
6.10 
mg/ml 
6.10 
mg/ml 
6.10 
mg/ml 
6.10 
mg/ml 
Sodium 
hydroxide 
QS to 
adjust pH 
QS to 
adjust pH 
QS to 
adjust pH 
QS to 
adjust pH 
QS to 
adjust pH 
QS to 
adjust pH 
Water for 
injection 
QS QS QS QS QS QS 
 
 
 Preservative Efficacy Test for Timolol maleate0.5% Ophthalmic Solution60 
 
 All useful antimicrobial agents are toxic substances. For maximum 
protection of patients, the concentration of preservative shown to be effective in the 
final packaged product should be below a level that may be toxic to human being.  
 The concentration of an added antimicrobial preservative can be kept at 
minimum if active ingredients of the formulation possess an intrinsic antimicrobial 
activity.  
 Sample from all six batches were subjected to preservative efficacy test of 
Benzalkonium chloride in Timolol maleate 0.5% ophthalmic solution. The most 
stringent criteria of British pharmacopoeia was followed for experiment. 
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Test organisms:  
            Following micro-organisms supplied by National Chemical Laboratory, 
Pune were used for the PET of Benzalkonium chloride. i) Candida albicans ATCC 
10231 ii) Aspergillus niger ATCC 16404 iii) Escherichia coli ATCC 8739 iv) 
Pseudomonas aeruginosa ATCC 9027 v) Staphylococcus aureus ATCC 6538  
Media:  Media for experiment were procured from  HIGH Media Mumbai   i) 
Soybean – Casein Digest Broth  ii) Soybean – Casein Digest Agar iii) Sabouraude - 
Dextrose Agar iv) Sabouraude – Dextrose Broth.   
 
Test Procedure for Anti-Infective Effectiveness  
1.  The product had been transferred to five sterile, capped bacteriological 
containers. 
2. Each container was inoculated with one of the prepared and standardized 
inoculums and mixed. 
3. The volume of suspension inoculum was between 0.5% and 1.0% of the volume 
of product. 
4. The concentration of test microorganism added to the product was such that the 
final concentration of the test preparation after inoculation was between 1105 and 
1106 cfu/ml of the product. 
5. Sample was incubated at 22.5 ± 250C. The initial concentration of viable 
microorganisms was determined by plate count method.  
6. Each container was sampled at intervals of 0 hrs, 6hrs, 24 hrs, 7days, 14 days, 21 
days, and 28days for different microorganisms. 
7. Sample was extracted into neutralizing fluid to inactivate residual preservative 
8. Using the calculated concentration of cfu/ml present at the initial of the test,          
calculate the change in log10 values of the concentration ( cfu/ml) for each micro- 
organism at the applicable test intervals, and express the changes in terms of log 
reduction. 
9. Microbial Count (cfu/ml) of Product was calculated by using following formula 
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Fig7: 
Preservative Efficacy Test procedure. 
 
Table 18: Criteria of log reduction for ophthalmic solution as per BP 
 
S. No. Microorganisms Acceptance Criteria 
1 Bacteria 
Bacteria reduced by 2 logs at 6 
hours and 3 logs at 24 hours 
with no recovery at 28 days. 
2 Fungi 
Fungi reduced by 2 logs at 7 
days with no increase at 28 
days. 
 
 After performing the preservative efficacy test for all the six batches, the 
batch of optimized formula was subjected to initial analysis. The optimized batch 
was filled aseptically in three different types of containers viz. Three piece 
container, BFS container, and amber colored glass container.   
 
 
 
                                   Ml of the inoculum of the product  cfu/ml of inoculum 
cfu/ml of Product =  
                                           Volume of reconstituted product 
               Log reduction = Log of initial count – Log of final count   
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 Stability and Container Compatibility Study61 : 
 Batch of Timolol maleate 0.5% ophthalmic solution was optimized from the 
results of PET was filled in to Glass container and LDPE container viz. Three Piece 
and BFS containers. The material of construction used for containers are as follows  
1. Three piece containers      : PE 1840 H 
2. BFS containers                  : PE 3020 D 
3. Glass containers                 : Type I: Borosilicate glass 
 
 Above mentioned PE 1840 H and PE 3020 D are the grades of low density 
polyethylene. Polyethylene is a long chain polymer of repeating groups, each 
connected to two hydrogen atoms. The individual molecules are very long with a 
carbon“backbone”formed by the carbon atoms connecting to each other. The 
polymer contains millions of these long molecular chains, each hopelessly entangled 
with all of its neighbors. The strength of the molded part lies in the complexity of 
that entanglement. When cross linking occurs, the molecular weight increases with 
resulting improvement of the physical properties of the polyethylene.  
Cross linking polyethylene compounds contain chemical agents designed to 
create a molecular change during the molding process, which results in the polymer 
molecules becoming interlocked (Cross linked) with each other. Other polyethylene 
resins bond with each other during the molding process by surface attachment only, 
while Crosslink creates a chemical interlocking bond between the molecules that is 
“in a sense” one giant molecule. 
 
 Stability : 
The design of the formal stability studies for the drug product should be 
based on knowledge of the behavior and properties of drug substance and from 
stability studies on the drug substances. The likely changes on storage and the 
rationale attributes to be tested in formal stability studies should be stated. 
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Table 19: Stability Protocol 
PRODUCT TIMOLOL MALEATE OPHTHALMIC SOLUTION 0.5% w/v 
Pack: 3-Piece, BFS, and 
Amber colored glass 
vials 
Condition 
Time 
points 
Analytical parameters 
Number 
of 
samples 
Description, 
Assay 
Preservative 
content 
Osmolality pH 
Drop 
size 
study 
Water 
Loss 
study 
Initial - 4 2 1 2 3 5* 
12 + 
05* 
60°C 
(stress 
testing) 
1week 4 2 1 2 - - 09 
2 week 4 2 1 2 -  09 
40
°
C± 2
°
C/ 
NMT     25 
%  R H 
(accelerated 
testing) 
1 
month 
4 2 1 2 3 # 12 
2 
month 
4 2 1 2 3 # 12 
3 
month 
4 2 1 2 3 # 12 
Total 71 
* The containers should be weighed individually before charging. 
# Parameter repeated at every station 
 Specifications 
Stability studies should include testing of those attributes of the drug product 
that are susceptible to change during storage and are likely to influence quality, 
safety, and / or efficacy. The testing should cover, as appropriate, the physical, 
chemical, biological and microbiological attributes, preservative content and 
functionality tests. Analytical procedures should be fully validated and stability 
indicating. 
 Testing frequency   
 At the accelerated storage condition, a minimum of three time points, 
including the initial and final time points (e.g., 0, 3, and 6 months) from a 6 month 
study is recommended. 
 Storage condition for Stability/Container compatibility 
 In general drug product should be evaluated under storage conditions (with 
appropriate tolerances) that it’s thermal stability and, if applicable, its sensitivity to 
moisture or potential for solvent loss. Accelerated condition for semi-permeable 
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containers (40ºC ± 2ºC/  NMT 25% RH) and for glass containers (40ºC ± 2ºC/ 75% 
± 5% RH) were chosen for storage for stability/compatibility study. 
 Product Analysis  
The product analysis was done as per the stability protocol. While 
manufacturing the in-process tests such as clarity, particulate matter, pH, were 
performed. Finished product tests include appearance, assay of API and 
preservative, osmolality, pH, drop size study, and water loss study at every time 
point of the stability. 
 Finished Product Analysis  
Finished product must be analyzed before the stability charging. These tests 
were performed initially and at every time point of the stability. All the analytical 
procedures were validated.  
ANALYTICAL PARAMETERS TO BE TESTED ARE AS FOLLOWS. 
 
1. Appearance:  
         Sample under test was inspected visually for color and clarity. 
2. Assay of Timolol maleate: 
USP recommends high performance liquid chromatography for assay of  
Timolol maleate 0.5% ophthalmic solution.  
 
i. Mobile Phase:  
  A filtered and degassed mixture of Buffer solution(pH 2.8) and  acetonitrile, 
(65:35) was prepared. The pH was adjusted to 2.50 ± 0.05 with 1M HClO4 or 1N 
sodium hydroxide and was filtered through 0.45 µm filter. 
ii. Resolution solution:  
No separate resolution solution is required. The mobile phase itself acts as 
resolution solution.  
iii. Standard preparation:  
Accurately weighed quantity of USP Timolol maleate was quantitatively 
dissolved in mixture of pH 2.8 buffer and acetonitrile (1:2 ratio) to obtain a 
solution having a known concentration of about 0.06 mg per ml. 
 
 
 
69 
 
iv. Assay preparation:  
Accurately weighed measured volume of ophthalmic solution, equivalent to 
5 mg of Timolol maleate, to a 50 ml volumetric flask, dilute with solution of pH 
2.8 buffer and acetonitrile (1:2 ratio) to volume and mixed. 
 
Table 20: Chromatographic conditions for Timolol maleate assay 
Column 150 mm x 4.6 mm; 3μ, Intersil ODS   
Flow rate  1.5 ml/min 
Detector wave length 295 nm 
Column temperature 35º C  
Injection volume 20 μl 
Run time 20 minutes 
Diluent 
pH 2.8 buffer and acetonitrile  
(1:2 ratio) 
 
 
v. Procedure:  
Equal volumes of the (about 20µl) of the standard preparation and assay 
preparation was injected separately into the chromatographic system, 
chromatograms were recorded, and the areas for major peaks were measured. 
Percentage assay of Timolol maleate was calculated by formula  
AI  x WS  x 5     x   50   x  P   x  100 =------------  % w/v 
AS     100    50        WT    100      LC   
 
AI : Area of Timolol maleate sample peak in sample preparation. 
AS : Average area of Timolol maleate standard  
WS : Weight of  Timolol maleate standard taken (in grams) 
WT : Weight of Timolol maleate sample taken (in grams) 
  P : Potency of Timolol maleate sample on as is basis
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3. Assay of Benzalkonium chloride :  
Assay of preservative Benzalkonium chloride was performed at every station 
of stability by High performance liquid chromatography method as follows. 
 
i. Buffer:  
Accurately 9.0 ml of perchloric acid was pippeted out and diluted to 
1000 ml of milli Q water. 
 
ii. Mobile phase:  
  Buffer and Acetonitrile was mixed in the ratio of 35 : 65.The pH was 
adjusted to 2.50 ± 0.05 with 1M HClO4 or 1N Sodium hydroxide and was 
filtered through 0.45 µm filter. 
 
iii. Standard Solution:  
             Equivalent to 50 mg of Benzalkonium chloride standard was accurately 
weighed into 100 ml volumetric flask; 35 ml of Mobile phase was added and 
dissolved. The volume was made with the Mobile phase. 
             5.0 ml of the above solution was transferred in to 100 ml volumetric flask 
and volume was made with the Mobile phase. The solution was filtered through the 
0.45 µm Nylon filter. 
 
iv. Test solution:   
The contents of 2 containers of Timolol maleate eye drop were mixed. 5.0ml 
of Timolol maleate ophthalmic solution was transferred in to a clean and dry 20 
ml volumetric flask and sample weight was recorded. Add 10.0 ml of diluent, 
shaked well.  The volume was made with the Mobile phase and the solution was 
filtered through the 0.45 µm Nylon filter. 
 
The chromatographic conditions for Benzalkonium chloride assay are listed in the 
table 21 
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Table 21: Chromatographic conditions for Benzalkonium chloride assay 
Column Hypersil BDS C8-150 x 4.6 mm, 5µ 
Flow rate  1.3 ml/min 
Detector wave length 219nm 
Column temperature 25°C 
Injection volume 20 µl 
Run time 20 min 
Diluent: mobile phase as diluents 
 
v.  Procedure:  
      20 µl of blank (single), standard solution (5 replicates) and test solution (2 
replicates) were injected separately. Chromatograms were recorded. Amount of 
Benzalkonium chloride was calculated using the formula. 
 
i. The tailing factor of Benzalkonium chloride NLT 2.0 
ii. The RSD of 5 replicate injections of standard NMT 2.0% 
AT  x WS  x 5     x   20   x P x Wt/ml x 100 =------------  % w/v 
AS     100    100      WT 
 
Where,   
AT: Area Benzalkonium chloride (BKC 1 + BKC 2) peak in sample preparation. 
AS: Average area of standard (BKC 1 + BKC 2). 
WS: Weight of standard taken (in grams) 
WT: Weight of Benzalkonium chloride taken (in grams) 
  P: Potency of Benzalkonium chloride on as is basis
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4. pH:  
          Precalibrated digital pH meter was used for the pH measurement of Timolol 
maleate ophthalmic solution.  
Procedure: 
1. The equipment was switched on by pressing the ON/OFF key. Display showed   
main screen after initial checks. 
2. Electrode was rinsed with distilled water and blotted dry with tissue paper  
3. Electrode and temperature probe were dipped in sample solution. 
4. By pressing ‘MODE’ key pH was selected. 
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5. ‘MEAS’ was selected to check the pH. 
6. After stabilization reading for pH was noted.    
7. Again glass electrode was flushed with water and wiped out. it was placed back in 
bottle congaing buffer solution. 
 
5. Osmolality:   
        Precalibrated digital osmometer was used for the osmolarity measurement of 
Timolol maleate ophthalmic solution.  
Procedure: 
1. Instrument was switched on and waited till initialization completed. 
2. ‘START’ key was pressed and waited till Running Diagnostic completed. 
3. 250 µl of the sample was pipette out in sample tube with help of micro pipette and 
micro-tip. 
4. The probe and stir/freeze wire was cleaned and wiped. 
5. ‘START’ key was pressed and data for sample number was entered. Again         
‘START’ key was pressed 
6. Note the reading for osmolality in mOsmol on digital display. 
7. Empty sample tube was leaved in freezing chamber to avoid deposition of debris. 
 
6. Drop size:   
             Drop size of instilled drop is the function of the amount of drug delivered 
to the eye per instillation. It is reported that that average drop size of many 
commercially available topical medication is actually 39 µl with range of 25.1 µl 
to 56.4 µl
64
. 
Procedure 
1. Container was punctured with piercing cap.  
2. Container was held with thumb and index finger in inverted position at an angle of 
90
0
. 
3. Pressure was applied to the container; separate drops will come out of the nozzle. 
4. Weight of 10 drops was taken with precision scales. 
5. Average was calculated for weight of single drop as follows 
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6. In same way, procedure was repeated for three times. From these three 
observations, average volume of the drop was calculated.   
 
 
7. Water loss:  
1. Five Semi-permeable containers of each type, LDPE Three piece and BFS, were 
charged to accelerated condition of temperature and humidity(40ºC ± 2ºC/ 25% ± 
5% RH)  with proper labeling on each container. 
2. Before charging, each container was weighed individually for initial weights. 
3. At every station of stability, each container was individually weighed and noted. 
4. Percentage water loss was calculated by using formula -                         
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
Weight of each drop (drop size) = Weight of 10 drops/10 
 
                               (Initial weight of container – final weight of container) × 100 
% Water Loss =    ----------------------------------------------------------------------------         
                                                     Initial weight of container  
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7. RESULTS AND DISCUSSIONS 
 PREFORMULATION STUDIES:  
           The Preformulation studies like Physical characterization and Analytical 
characterization of drug sample including description, identification, melting point, 
solubility, loss on drying, and assay by potentiometric titration method were 
performed. 
 PHYSICAL CHARACTERIZATION OF DRUG SAMPLE  
Timolol Maleate was supplied by Syn-tech pharma, Taiwan, was found to comply 
for its identification and authenticity as per certificate of analysis provided by 
supplier. 
            The drug was physically characterized according to following methods- 
1. Description : 
  The received sample of Timolol maleate after visual observation and under 
compound microscope it was found to show the following characteristics and these 
are acceptable according to British Pharmacopoeia and Ph Eur 2007. 
             a) Nature of drug sample: Crystalline powder 
 b) Color of drug sample:    White 
2. Loss on Drying:  
        After drying 1.0 g of sample at 100
0
 C for 4 hours in hot air oven. It was found 
that weight of sample reduced to 0.82 g. Sample passed the criteria for loss on 
drying. (NMT 0.5%). 
3. Solubility:  
        It was found that drug was readily soluble in water for injection , slightly 
soluble to soluble in Chloroform, slightly soluble in methanol. Timolol maleate got 
solubilised in water for injection at pH 6.8. 
 
 ANALYTICAL CHARACTERIZATION 
1. Absorbance:  
       The absorbance of the 0.5 g of Timolol maleate dissolved in 0.1M HCl solution 
measured at 294 nm was found to be 0.27 using UV – visible spectrophotometer. 
                                  
2. Optical Rotation:  
       After dissolving the drug sample in given proportion of 0.1N hydrochloric acid 
the angle of optical rotation was found to be -11.9
0
. 
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3. Assay:  
       After performing assay of Timolol maleate by potentiometrically by using the 
digital potentiometer, assay of Timolol maleate sample was found to be 98.603%. 
Percentage purity of Timolol maleate must be calculated for the addition of exact 
quantity to achieve the concentration of 5 mg/ml in ophthalmic solution. 
After designing of prototype formulation, six different batches with different 
concentration of Benzalkonium chloride were taken. All these six batches were 
subjected to the Preservative efficacy test as per the BP. 
 Results of Preservative Efficacy Test:  
Log reduction for each type of micro-organism was calculated using the given 
formula. Table showing Log reductions in microbial growth are given below.   
 
 Batch No. OPT/TIM/T-001 (BAK – 0.0% v/v) 
 
 
Log reduction at 6
th
 hours 
Escherichia coli 02 × 10
5-
01 × 10
5
 5.3-5.0 0 log reduction 
Pseudomonas 
aeruginosa 
02 × 10
5-
01 × 10
5
 5.3-5.0 0 log reduction 
Staphylococcus 
aureus 
03 × 10
5
-02 × 10
5
 5.4-5.3 0 log reduction 
Candida albicans 01×10
6
 - 01×10
6
 6.0 – 6.0 0 log reduction 
Aspergillus niger 03×10
5
 -2×10
5
 5.4 -5.3 0 log reduction 
         
 
Log reduction at 24
th
 hours 
Escherichia coli 02 × 10
5-
01 × 10
5
 5.3-5 0 log reduction 
Pseudomonas 
aeruginosa 
02 × 10
5-
01 × 10
5
 5.3-5 0 log reduction 
Staphylococcus 
aureus 
03 × 10
5 
- 01 × 10
5
 5.4 -5.0 0 log reduction 
Candida albicans 5.3 -4.3 6.0 – 6.0 0 log reduction 
Aspergillus niger 03×10
5 
- 03×10
5
 5.4 -5.4 0 log reduction 
 
 
 
Log reduction at 7
th
 day 
Escherichia coli 02 × 10
5-
03 × 10
4
 5.3 -4.4 1 log reduction 
Pseudomonas 
aeruginosa 
02 × 10
5- 
02 × 10
4
 5.3 -4.3 1 log reduction 
Staphylococcus 
aureus 
03 × 10
5 – 01× 104 5.3 -4.0 1 log reduction 
Candida albicans 5.3 - 4.3 6.0 – 6.0 0 log reduction 
Aspergillus niger 03×10
5 
- 03×10
5
 5.4 -5.4 0 log reduction 
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Log reduction at 14
th
 day 
Escherichia coli 02 × 10
5
 - 02 × 10
4
 5.3 -4.3 1 log reduction 
Pseudomonas 
aeruginosa 
02 × 10
5- 
02 × 10
4
 
5.3 -4.3 1 log reduction 
Staphylococcus 
aureus 
03 × 10
5 – 01× 105 5.4-4.0 1 log reduction 
Candida albicans 01×10
6
 - 01×10
6
 6.0 – 6.0 0 log reduction 
Aspergillus niger 03 × 10
5 – 02× 105 5.4-5.3 0 log reduction 
 
 
Log reduction at 21
th
 day 
Escherichia coli 02 × 10
5
 - 02 ×10
4
 5.3 -4.3 1 log reduction 
Pseudomonas 
aeruginosa 
02 × 10
5
 - 01 ×10
4
 5.3 -4.0 1 log reduction 
Staphylococcus 
aureus 
03 × 10
5 – 01× 104 5.4-4.0 1 log reduction 
Candida albicans 01×10
6
 - 01×10
6
 6.0 – 6.0 0 log reduction 
Aspergillus niger 03 × 10
5 – 02× 105 5.4-5.3 0 log reduction 
 
Log reduction at 28
th
 day 
Escherichia coli 02 × 10
5
 - 01 ×10
4
 5.3 -4.0 1 log reduction 
Pseudomonas 
aeruginosa 
02 × 10
5
 - 01 ×10
4
 5.3 -4.0 1 log reduction 
Staphylococcus 
aureus 
03 × 10
5 – 01× 104 5.4-4.0 1 log reduction 
Candida albicans 01×10
6
 - 02×10
5
 6.0 – 5.3 1 log reduction 
Aspergillus niger 03 × 10
5 – 01× 104 5.4-4.0 1 log reduction 
 
 
 Batch No. OPT/TIM/ T-002 (BAK – 0.01% v/v) 
Log reduction at 6
th
 hours 
Escherichia coli 01 × 10
5
 – 2 × 104 5.0 - 4.3 1 Log reduction 
Pseudomonas 
aeruginosa 
02 × 10
5
 - 2 × 10
4
 5.3 - 4.3 1 Log reduction 
Staphylococcus 
aureus 
02 × 10
5
 - 2 × 10
4
 5.3 - 4.3 1 Log reduction 
Candida albicans 01 × 10
6
 - 01 × 10
6
 6.0 - 6.0 0 Log reduction 
Aspergillus niger 03 × 10
5
 - 01 × 10
5
 5.4 – 5.0 0 Log reduction 
         
Log reduction at 24
th
 hours 
Escherichia coli 01 × 10
5
 – 3 × 103 5.0 - 3.0 2 Log reduction 
Pseudomonas 
aeruginosa 
02 × 10
5
 - 1 × 10
3
 5.3 – 3.0 2 Log reduction 
Staphylococcus 
aureus 
02 × 10
5
 - 2 × 10
3
 5.3 - 3.3 2 Log reduction 
Candida albicans 01 × 10
6
 - 01 × 10
6
 6.0 – 6.0 0 Log reduction 
Aspergillus niger 03 × 10
5
 - 01 × 10
5
 5.4 – 5.0 0 Log reduction 
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Log reduction at 7
th
 day 
Escherichia coli 01 × 10
5
 – NIL 5.0 - NIL  5 Log reduction 
Pseudomonas 
aeruginosa 
02 × 10
5
 – NIL 5.3 - NIL 5 Log reduction 
Staphylococcus 
aureus 
02 × 10
5
 – NIL 5.3 - NIL 5 Log reduction 
Candida albicans 01 × 10
6
 - 02 ×10
5
 6.0 – 5.3 1 Log reduction 
Aspergillus niger 03 × 10
5
 - 02 ×10
4
 5.4 – 4.3 1 Log reduction 
 
 
Log reduction at 14
th
 day 
Escherichia coli 01 × 10
5
 – NIL 5.0 - NIL  5 Log reduction 
Pseudomonas 
aeruginosa 
02 × 10
5
 - NIL 5.3 - NIL 5 Log reduction 
Staphylococcus 
aureus 
02 × 10
5
 - NIL 5.3 - NIL 5 Log reduction 
Candida albicans 01 × 10
6
 - 02 ×10
5
 6.0 – 5.3 1 Log reduction 
Aspergillus niger 03 × 10
5
 - 02 × 0
4
 5.4 – 4.3 1 Log reduction 
 
 
Log reduction at 21
th
 day 
Escherichia coli 01 × 10
5
 – NIL 5.0 - NIL  5 Log reduction 
Pseudomonas 
aeruginosa 
02 × 10
5
 - NIL 5.3 - NIL 5 Log reduction 
Staphylococcus 
aureus 
02 × 10
5
 - NIL 5.3 - NIL 5 Log reduction 
Candida albicans 01 × 10
6
 - 02 × 10
5
 6 – 5.3 1 Log reduction 
Aspergillus niger 03 × 10
5
 - 02 × 10
4
 5.4 – 4.3 1 Log reduction 
 
 
Log reduction at 28
th
 day 
Escherichia coli 01 × 10
5
 – NIL 5.0 - NIL  5 Log reduction 
Pseudomonas 
aeruginosa 
02 × 10
5
 - NIL 5.3 - NIL 5 Log reduction 
Staphylococcus 
aureus 
02 × 10
5
 - NIL 5.3 - NIL 5 Log reduction 
Candida albicans 01 × 10
6
 - 02 × 0
5
 6 – 5.3 1 Log reduction 
Aspergillus niger 03 × 10
5
 - 02 × 0
4
 5.4 – 4.3 1 Log reduction 
 
 
 
 Batch No. OPT/TIM/T-003 (BAK – 0.012% v/v) 
Log reduction at 6
th
 hours 
Escherichia coli 02 × 10
5 -
03 × 10
3
 5.3 -3.3 2 Log reduction 
Pseudomonas 
aeruginosa 
01 × 10
5 -
01 × 10
3
 5.0 – 3.0 2 Log reduction 
Staphylococcus 
aureus 
03 × 10
5
 - 01 ×10
3
 5.4 – 3.0 2 Log reduction 
Candida albicans 01 × 10
6
 - 01 ×10
6
 6.0 -6.0 0 Log reduction 
Aspergillus niger 03 × 10
5
 - 01 ×10
5
 5.4 – 5.0  0 Log reduction 
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Log reduction at 24
th
 hours 
Escherichia coli 02 × 10
5
 – 4 × 102 5.3 - 2.6 3 Log reduction 
Pseudomonas 
aeruginosa 
01 × 10
5
 - 2 × 10
5
 5.0 – 2.3 3 Log reduction 
Staphylococcus 
aureus 
03 × 10
5
 - 4 × 10
2
 5.4 - 2.6 3 Log reduction 
Candida albicans 01 × 10
6
 - 01 × 0
6
 6 – 6 0 Log reduction 
Aspergillus niger 03 × 10
5
 – 2 × 105 5.4 - 5.0 0 Log reduction 
 
 
Log reduction at 7
th
 day 
Escherichia coli 02 × 10
5
 – NIL 5.3 - NIL  5 Log reduction 
Pseudomonas 
aeruginosa 
01 × 10
5
 – NIL 5.0 - NIL 5 Log reduction 
Staphylococcus 
aureus 
03 × 10
5
 – NIL 5.4 - NIL 5 Log reduction 
Candida albicans 01 × 10
6
 - 01 × 0
5
 6.0 – 5.0 1 Log reduction 
Aspergillus niger 03 × 10
5
 - 02 ×10
4
 5.4 – 4.3 1 Log reduction 
 
 
Log reduction at 14
th
 day 
Escherichia coli 02 × 10
5
 – NIL 5.3 - NIL 5 Log reduction 
Pseudomonas 
aeruginosa 
01 × 10
5
 – NIL 5.0 - NIL 5 Log reduction 
Staphylococcus 
aureus 
03 × 10
5
 – NIL 5.4 - NIL 5 Log reduction 
Candida albicans 01 × 10
6
 - 01 × 0
5
 6.0 – 5.0 1 Log reduction 
Aspergillus niger 03 × 10
5
 - 02 ×10
5
 5.4 – 4.4 1 Log reduction 
 
 
Log reduction at 21
th
 day 
Escherichia coli 02 × 10
5
 – NIL 5.3 – NIL  5 Log reduction 
Pseudomonas 
aeruginosa 
01 × 10
5
 – NIL 5.0 – NIL 5 Log reduction 
Staphylococcus 
aureus 
03 × 10
5
 – NIL 5.4 – NIL 5 Log reduction 
Candida albicans 01 × 10
6
 - 01 × 0
5
 6.0 – 5.0 1 Log reduction 
Aspergillus niger 03 × 10
5
 - 02 ×10
4
 5.4 – 4.3 1 Log reduction 
 
 
Log reduction at 28
th
 day 
Escherichia coli 02 × 10
5
 – NIL 5.3 – NIL  5 Log reduction 
Pseudomonas 
aeruginosa 
01 × 10
5
 – NIL 5.0 – NIL 5 Log reduction 
Staphylococcus 
aureus 
03 × 10
5
 – NIL 5.4 – NIL 5 Log reduction 
Candida albicans 01 × 10
6
 - 01 × 0
5
 6.0 – 5.0 1 Log reduction 
Aspergillus niger 03 × 10
5
 - 01 ×10
4
 5.4 – 4..0 1 Log reduction 
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 Batch No. OPT/TIM/T-004(BAK – 0.016% v/v) 
Log reduction at 6
th
 hours 
Escherichia coli 01 × 10
5
 – 2 × 102 5.0 - 2.3 3 Log reduction 
Pseudomonas 
aeruginosa 
01 × 10
5
 - 2 × 10
2
 5.0 - 2.3 3 Log reduction 
Staphylococcus 
aureus 
02 × 10
5
 - 1 × 10
3
 5.3 – 3.0 2 Log reduction 
Candida albicans 01 × 10
6
 - 01 ×10
6
 6.0 – 6.0 0 Log reduction 
Aspergillus niger 02 × 10
5
 - 02 × 0
5
 5.3 – 5.3 0 Log reduction 
 
 
Log reduction at 24
th
 hours 
Escherichia coli 01 × 10
5
 – 2 × 102 5.0 - 2.3 3 Log reduction 
Pseudomonas 
aeruginosa 
01 × 10
5
 - 2 × 10
2
 5.0 - 2.3 3 Log reduction 
Staphylococcus 
aureus 
02 × 10
5
 -  1 × 10
3
 5.3 - 3 2 Log reduction 
Candida albicans 01 × 10
6
 - 02 ×10
5
 6.0 – 5.3 1 Log reduction 
Aspergillus niger 02 × 10
4
 - 02 ×10
4
 5.3 – 4.3 1 Log reduction 
 
Log reduction at 7
th
 day 
Escherichia coli 01 × 10
5
 – NIL 5.0 - NIL 5 Log reduction 
Pseudomonas 
aeruginosa 
01 × 10
5
 - NIL 5.0 - NIL 5 Log reduction 
Staphylococcus 
aureus 
02 × 10
5
 - NIL 5.3 - NIL 5 Log reduction 
Candida albicans 01× 10
6
 - 01 ×10
5
 6.0 – 5.0 1 Log reduction 
Aspergillus niger 02× 10
5
 - 02 ×10
4
 5.3 – 4.3 1 Log reduction 
 
Log reduction at 14
th
 day 
Escherichia coli 01 × 10
5
 – NIL 5.0 - NIL  5 Log reduction 
Pseudomonas 
aeruginosa 
02 × 10
5
 - NIL 5.3 - NIL 5 Log reduction 
Staphylococcus 
aureus 
02 × 10
5
 - NIL 5.3 - NIL 5 Log reduction 
Candida albicans 01 × 10
6
 - 01 ×10
4
 6.0 – 4.0 2 Log reduction 
Aspergillus niger 02 × 10
5
 - 01 ×10
3
 5.3 – 3.0 2 Log reduction 
 
Log reduction at 21
th
 day 
Escherichia coli 01 × 10
5
 – NIL 5.0 - NIL 5 Log reduction 
Pseudomonas 
aeruginosa 
02 × 10
5
 - NIL 5.3 - NIL 5 Log reduction 
Staphylococcus 
aureus 
02 × 10
5
 - NIL 5.3 - NIL 5 Log reduction 
Candida albicans 01 × 10
6
 - 01 ×10
4
 6.0 – 4.0 2 Log reduction 
Aspergillus niger 02 × 10
5
 - 01 ×10
3
 5.3 – 3.0 2 Log reduction 
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Log reduction at 28
th
 day 
Escherichia coli 01 × 10
5
 – NIL 5.0 - NIL  5 Log reduction 
Pseudomonas 
aeruginosa 
02 × 10
5
 – NIL 5.3 - NIL 5 Log reduction 
Staphylococcus 
aureus 
02 × 10
5
 – NIL 5.3 - NIL 5 Log reduction 
Candida albicans 01 × 10
6
 - 01 ×10
4
 6.0 – 4.0 2 Log reduction 
Aspergillus niger 02 × 10
5
 - 01 ×10
3
 5.3 – 3.0 2 Log reduction 
 
 
 Batch No. OPT/TIM/T-005 (BAK – 0.02% v/v) 
 
Log reduction at 6
th
 hours 
Escherichia coli 01 × 10
5
 – 1 × 103 5.0 – 3.0 2 Log reduction 
Pseudomonas 
aeruginosa 
01 × 10
5
 - 1 × 10
3
 5.0 – 3.0 2 Log reduction 
Staphylococcus 
aureus 
02 × 10
5
 -  1 × 10
3
 5.3 – 3.0 2 Log reduction 
Candida albicans 01 × 10
6
 - 01 × 0
6
 6.0– 6.0 0 Log reduction 
Aspergillus niger 04 × 10
5
 - 02 × 0
5
 5.6 – 5.3 0 Log reduction 
         
 
Log reduction at 24
th
 hours 
Escherichia coli 01 × 10
5
 – NIL 5.0 - NIL  5 Log reduction 
Pseudomonas 
aeruginosa 
01 × 10
5
 - NIL 5.0 - NIL 5 Log reduction 
Staphylococcus 
aureus 
02 × 10
5
 -  NIL 5.3 - NIL 5 Log reduction 
Candida albicans 01 × 10
6
 - 01 ×10
5
 6.0 – 5.0 1 Log reduction 
Aspergillus niger 04 × 10
5
 - 01 ×10
4
 5.6 – 4.0 1 Log reduction 
 
Log reduction at 7
th
 day 
Escherichia coli 01 × 10
5
 – NIL 5.0 - NIL  5 Log reduction 
Pseudomonas 
aeruginosa 
01 × 10
5
 - NIL 5.0 - NIL 5 Log reduction 
Staphylococcus 
aureus 
02 × 10
5
 - NIL 5.3 - NIL 5 Log reduction 
Candida albicans 01 × 10
6
 - 02 × 10
4
 6.0 – 4.3 2 Log reduction 
Aspergillus niger 04 × 10
5
 - 02 × 10
4
 5.6 – 4.3 2 Log reduction 
 
Log reduction at 14
th
 day 
Escherichia coli 01 × 10
5
 – NIL 5.0 – NIL  5 Log reduction 
Pseudomonas 
aeruginosa 
02 × 10
5
 - NIL 5.3 – NIL 5 Log reduction 
Staphylococcus 
aureus 
02 × 10
5
 - NIL 5.3 – NIL 5 Log reduction 
Candida albicans 01 × 10
6
 - 02 × 10
3
 6.0 – 3.3 3 Log reduction 
Aspergillus niger 04 × 10
5
 - 03 × 10
3
 5.6 – 3.3 3 Log reduction 
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Log reduction at 21
th
 day 
Escherichia coli 01 × 10
5
 – NIL 5.0 - NIL  5 Log reduction 
Pseudomonas 
aeruginosa 
02 × 10
5
 - NIL 5.3 - NIL 5 Log reduction 
Staphylococcus 
aureus 
02 × 10
5
 - NIL 5.3 - NIL 5 Log reduction 
Candida albicans 01 × 10
6
 – 1×102 6.0 – 2.0 4 Log reduction 
Aspergillus niger 04 × 10
5
 - 01 × 10
2
 5.6 – 2.0 4 Log reduction 
 
 
Log reduction at 28
th
 day 
Escherichia coli 01 × 10
5
 – NIL 5.0 - NIL  5 Log reduction 
Pseudomonas 
aeruginosa 
02 × 10
5
 - NIL 5.3 - NIL 5 Log reduction 
Staphylococcus 
aureus 
02 × 10
5
 - NIL 5.3 - NIL 5 Log reduction 
Candida albicans 01 × 10
6
 - 01 × 10
2
 6.0 – 2.0 4 Log reduction 
Aspergillus niger 04 × 10
6
 - 01 × 10
2
 6.0 – 2.0 4 Log reduction 
 
 BATCH NO. OPT/TIM/T-06 (BAK – 0.022% v/v) 
 
Log reduction at 6
th
 hours 
Escherichia coli 02 × 10
5
- 02 × 10
3 
 5.3- 3.3 2 Log reduction 
Pseudomonas 
aeruginosa 
01 × 10
5
- 01 × 10
3 
 5.0- 3.0 2 Log reduction 
Staphylococcus 
aureus 
02 × 10
5
- 02 × 10
3 
 5.3- 3.3 2 Log reduction 
Candida albicans 01 × 10
6
 - 01 ×10
6
 6.0 – 6.0 0 Log reduction 
Aspergillus niger 02 × 10
5
- 01 × 10
5 
 5.3- 5.0 0 Log reduction 
        
 
Log reduction at 24
th
 hours 
Escherichia coli 02 × 10
5
- NIL
 
 5.3- 0.0 5 Log reduction 
Pseudomonas 
aeruginosa 
01 × 10
5
- NIL
 
 5.0- 0.0 5 Log reduction 
Staphylococcus 
aureus 
02 × 10
5
- NIL
 
 5.3- 0.0 5 Log reduction 
Candida albicans 01 × 10
6
 - 01 ×10
5
 6.0 – 5.0 1 Log reduction 
Aspergillus niger 02 × 10
5
- 01 × 10
4 
 5.3- 4.0 1 Log reduction 
 
 
Log reduction at 7
th
 day 
Escherichia coli 02 × 10
5
- NIL
 
 5.3- 0.0 5 Log reduction 
Pseudomonas 
aeruginosa 
01 × 10
5
- NIL
 
 5.0- 0.0 5 Log reduction 
Staphylococcus 
aureus 
02 × 10
5
- NIL
 
 5.3- 0.0 5 Log reduction 
Candida albicans 01 × 10
6
 - 01 ×10
4
 6.0- 4.0 2 Log reduction 
Aspergillus niger 02 × 10
5
- 01 × 10
3
 5.3- 3.0 2 Log reduction 
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Log reduction at 14
th
 day 
Escherichia coli 02 × 10
5
- NIL
 
 5.3- 0.0 5 Log reduction 
Pseudomonas 
aeruginosa 
01 × 10
5
- NIL
 
 5.0- 0.0 5 Log reduction 
Staphylococcus 
aureus 
02 × 10
5
- NIL
 
 5.3- 0.0 5 Log reduction 
Candida albicans 01 × 10
6
 - 01 ×10
3
 6.0- 3.0 3 Log reduction 
Aspergillus niger 02 × 10
5
- 02 × 10
2
 5.3- 2.3 3 Log reduction 
 
 
Log reduction at 21
th
 day 
Escherichia coli 02 × 10
5
- NIL
 
 5.3- 0.0 5 Log reduction 
Pseudomonas 
aeruginosa 
01 × 10
5
- NIL
 
 5.0- 0.0 5 Log reduction 
Staphylococcus 
aureus 
02 × 10
5
- NIL
 
 5.3- 0.0 5 Log reduction 
Candida albicans 01 × 10
6
 - 03 ×10
2
 6.0- 2.4 4 Log reduction 
Aspergillus niger 02 × 10
5
- 02 × 10
1
 5.3- 1.3 4 Log reduction 
 
 
Log reduction at 28
th
 day 
Escherichia coli 02 × 10
5
- NIL
 
 5.3- 0.0 5 Log reduction 
Pseudomonas 
aeruginosa 
01 × 10
5
- NIL
 
 5.0- 0.0 5 Log reduction 
Staphylococcus 
aureus 
02 × 10
5
- NIL
 
 5.3- 0.0 5 Log reduction 
Candida albicans 01 × 10
6
 - 02 ×10
2
 6.0- 2.3 4 Log reduction 
Aspergillus niger 02 × 10
5
- 02 × 10
1
 5.3- 1.0 4 Log reduction 
 
 
 
 Summary of PET results : 
Results for Bacterial log reduction with different concentration of Benzalkonium 
chloride are summarized in following table 22. 
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Table 22: Log Reduction in Bacterial Growth. 
 
BAK 
CONCENTRATION 
OBSERVATION (LOG REDUCTION) 
6 HRS 24 HRS 7
th
 
DAY 
14
th
 
DAY 
21
th 
DAY 
28
th
 
DAY 
0.0% 0 0 1 1 1 1 
 0.010 % 1 2 5 5 5 5 
 0.012 % 2 3 5 5 5 5 
0.016 % 2 3 5 5 5 5 
0.020 % 2 5 5 5 5 5 
0.022 % 2 5 5 5 5 5 
Acceptance criteria Min 2 Log 
Reduction 
Min 3 Log 
Reduction 
- - - No 
Recovery 
 
 
 
Results for Fungal log reduction with different concentration of Benzalkonium 
chloride are summarized in following table 23. 
 
 
 
Table 23: Log Reduction in Fungal Growth. 
 
 
BAK 
CONCENTRATION 
OBSERVATION (LOG REDUCTION) 
6 
HRS 
24 
HRS 
7
th
 DAY 14
th
 
DAY 
21
th 
DAY 
28
th
 DAY 
0.0% 0 0 0 0 0 1 
 0.010 % 0 0 1 1 1 1 
 0.012 % 0 0 1 1 1 1 
0.016 % 0 0 1 2 2 2 
0.020 % 0 1 2 3 3 3 
0.022 % 0 1 2 3 4 4 
Acceptance criteria - - Min 2 
Log 
Reduction 
- - No 
Recovery 
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The results obtained from the experiment, in which  
1) Benzalkonium chloride (0.0%v/v) failed for 2 log reduction at 6 hours and 3 log 
reductions at 24 hours for bacteria. In case of fungi, Benzalkonium chloride 
(0.0%v/v) showed zero log reduction at 7
th
 day whereas criteria states that reduction 
must be of 2 log at 7
th
 day.  
2) Benzalkonium chloride (0.01%v/v) failed for 2 log reduction at 6 hours and 3 log 
reductions at 24 hours for bacteria. In case of fungi, Benzalkonium chloride (0.01% 
v/v) showed only 1 log reduction at 7
th
 day whereas criteria states that reduction 
must be of 2 log at 7
th
 day.  
3) Benzalkonium chloride 0.012 ml (0.012% v/v) showed 2 log reduction at 6 hours 
and 3 log reductions at 24 hours for bacteria. There are 5 log reductions at 28 days. 
In case of fungi, Benzalkonium chloride (0.012% v/v) showed only 1 log reduction 
at 7
th
 day whereas criteria states that reduction must be of 2 log at 7
th
 day. 
4) Benzalkonium chloride (0.016% v/v) passed criteria for bacteria for 2 log and 3 
log reductions at 6 hours and 24 hours respectively. There were 5 log reductions at 
28
th
 day means there was no recovery of bacteria. For fungi Benzalkonium chloride 
(0.016% v/v) failed to reduce fungus count by 2 log at 7
th
 day. It showed only 1 log 
reduction. Hence Benzalkonium chloride (0.016% v/v) passes only for bacteria but 
not for fungi. 
5) Benzalkonium chloride (0.02% v/v) showed 2 log reductions at 6 hours and 5 log 
reductions at 24 hours and no recovery at 28
th
 day for bacteria. For fungi it showed 
log reduction as stated in criteria, 2 log reductions at 7
th
 day and no recovery at 28
th
 
day. 
6) Benzalkonium chloride (0.024% v/v) passed criteria for bacteria for 2 log and 5 
log reductions at 6 hours and 24 hours respectively. There were 5 log reductions at 
28
th
 day means there was no recovery of bacteria. For fungi Benzalkonium chloride 
(120% w/v strength) reduced fungus count by 2 log at 7
th
 day. It also showed 4 log 
reductions at 28
th
 day. Hence Benzalkonium chloride (0.024% v/v) passes both for 
bacteria but and for fungi. 
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 RESULTS OF STABILITY/COTAINER COMPATIBILITY STUDY 
In stability/container compatibility study drug product was evaluated for assay of 
Timolol maleate and Benzalkonium chloride at initially, stress condition and at 
accelerated condition. Analysis was done by using HPLC. Other evaluated 
parameters are pH, Osmolality, Drop size and Water loss.  
 The chromatograms for assay of Timolol maleate at each time point of the 
stability are as shown below. 
  
1. Initial 
 
 
   
 
 
 
                  Fig 7: Chromatograms for Timolol maleate assay at Initial 
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2. Stress condition 
2.1 Three piece container  
 1week  
 
 
 
   
  2 weeks 
 
 
 
 
Fig 9: Chromatograms for Timolol maleate assay at Stress condition in Three 
piece containers. 
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2.2 BFS container 
 
1 week 
 
 
 
 
2 weeks 
 
 
 
 
Fig 10: Chromatograms for Timolol maleate assay at Stress condition in BFS 
containers. 
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2.3 Amber Colored Glass Containers  
1 week  
 
 
 
 
 
2 weeks  
 
 
 
 
 
Fig 11: Chromatograms for Timolol maleate assay at Stress condition in Glass 
containers. 
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3. Accelerated Condition 
3.1 Three Piece Container 
1 month 
 
 
2months 
 
 
3 months  
 
 
Fig 12: Chromatograms for Timolol maleate assay at accelerated condition in 
Three piece containers. 
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3.2  BFS container 
1 month  
 
 
2 months  
 
 
3 months 
 
Fig 13: Chromatograms for Timolol maleate assay at accelerated condition in 
BFS containers. 
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3.3 Amber Colored Glass Containers  
   1 month  
 
 
2 months 
 
 
3 months  
 
 
Fig 14: Chromatograms for Timolol maleate assay at accelerated condition in 
Glass containers. 
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Results for Timolol maleate assay are depicted in the Table 24 
Table 24: Assay of Timolol maleate 
S. 
No. 
 
Containers 
 
Specification Initial 
Stress condition Accelerated condition 
1Week 2Weeks 1Month 2Months 3Months 
1 Three piece 90- 110 101.5 100.77 99.93 100.95 100.14 99.94 
     
2 
BFS 90- 110 
101.5 100.42 99.13 100.3 99.52 97.11 
3 Glass 90- 110 101.5 99.46 97.5 99.67 98.50 96.61 
 
 
 
 
 
Fig 15: Graphical representation of Assay of Timolol maleate 
 
              Assay of Timolol maleate was evaluated at initial, at stress condition and at 
accelerated condition. Initially assay of Timolol maleate was found to be 101.5 %. 
At stress condition of temperature (60
0
C) up to two week assay decreased to 99.93% 
94 
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Time Period 
Timolol Assay at Accelerated Condition 
Three piece BFS Glass 
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in Three piece container; to 99.13% in BFS container; to 97.50% in amber colored 
glass container. At accelerated condition of temperature and relative humidity 
(40
°
C± 2
°
C/ NMT 25 % RH for plastic and 40
°
C± 2
°
C/ NMT 75 % RH for glass 
container) assay was estimated up to three months. Assay decreased to 99.94% in 
Three piece container, to 97.11 in BFS container and to 96.11% in Glass container 
up to the three month.  
Significant loss in assay was found in glass and BFS (3020 D) container as 
compared to Three piece container (PE 1840 H). Loss of Timolol maleate may be 
due to chemical interaction of cross linking present in the MOC of container with 
the components of drug product. Possibility is that the attachment of carbon atoms 
from Timolol maleate to long polymeric chain of carbon present in MOC. Another 
possible reason is that entrapment of Timolol maleate molecule in to the complex 
entanglement of polymer chain. In case of glass containers, interaction of rubber 
closure with product may responsible for the loss of drug by adsorption and/or 
chemical reaction. 
  
 The chromatograms for assay of Benzalkonium chloride are as shown below. 
 1. Initial  
 
 
Fig 16: Chromatograms for Benzalkonium chloride assay at Initial 
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2. Stress condition      
 2.1 Three piece container   
 1 week 
2weeks
 
 
Fig 17: Chromatograms for Benzalkonium chloride assay at Stress condition in 
Three piece containers. 
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2.2 BFS container 
 
1 week 
 
 
 
 
2weeks
 
Fig 18: Chromatograms for Benzalkonium chloride assay at Stress condition in 
BFS containers. 
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2.3 Glass container 
 
 1week 
 
 
2 weeks 
 
Fig 19: Chromatograms for Benzalkonium chloride assay at Stress condition in 
Glass containers. 
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3. Accelerated condition  
3.1 Three piece container 1month
 
2months 
3months
 
Fig 20: Chromatograms for Benzalkonium chloride assay at accelerated 
condition in Three piece containers. 
98 
 
3.2 BFS containers     
 
1month
 
 
  2months 
 
 
    3months
 
Fig 21: Chromatograms for Benzalkonium chloride assay at accelerated 
condition in BFS containers. 
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3.3 Glass containers  
1 month 
  
2 months 
 
3 months 
 
Fig 22: Chromatograms for Benzalkonium chloride assay at accelerated 
condition in Glass containers. 
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Results for Benzalkonium chloride assay are depicted in Table 25. 
Table 25: Assay of Benzalkonium chloride 
Fig 23: Graphical representation of assay of  Benzalkonium chloride Profile 
 
Similar to assay of Timolol maleate, assay of preservative Benzalkonium chloride 
was evaluated at initial, at stress condition and at accelerated condition. Initially 
assay of Benzalkonium chloride was found to be 104.15%. At stress condition of 
temperature (60
0
C) up to two week assay decreased to 102.89 % in Three piece 
container; to 101.27% in BFS container; to 102.24 in amber colored glass container.  
At accelerated condition of temperature and relative humidity (40
°
C± 2
°
C/ NMT 25 
% RH for plastic and 40
°
C± 2
°
C/ 75 ± 5% RH for glass container) assay was 
estimated up to three months.  
Significant loss in assay was found in glass and BFS container (100.05) as compared 
to Three piece container. Benzalkonium chloride has the tendency for adsorption on 
to the surface of plastic. Loss of preservative may be due to chemical adsorption of 
C
12 – C18 chain of macro molecule of Benzalkonium chloride. Hydrophobic or 
anionic surface of container polymer exhibits significant adsorption of cationic 
molecule of preservative. Amount adsorption makes the difference in assay of 
preservative. Preservative may also be lost to inhibit microbial growth. In case of 
glass containers interaction of rubber closure with product may responsible for the 
loss of drug by adsorption and/or chemical reaction. 
      
Sr. 
No. 
Containers 
Specification Initial 
Stress condition Accelerated condition 
1Week 2Weeks 1Month 2Months 3Months 
1 Three piece 80-120 104.15 103.52 102.89 103.96 103.57 102.84 
     
2 
BFS 80-120 104.15 103.48 101.27 103.70 101.30 100.05 
3 Glass 80-120 104.15 103.63 102.4 103.95 103.38 102.77 
101 
 
 pH:  
pH of the solution was determined by using Cyber scan

510
PC
 Eutech pH meter. 
Initial pH was found to be 6.82. After charging to stability /container compatibility 
study pH was determined for each type of container at every station of the stability. 
The results are tabulated as follows. 
Table 26:  pH observations 
 
 
 
 
Fig 24: Graphical representation of pH profile 
 
From the results it is found that, in accelerated condition up to the three month 
solution pH in Three piece container was decreased from 6.82 to 6.35. Solution pH 
in BFS container decreased to 6.28 and in glass container decreased to 6.30. At 
stress condition nearly same fall in pH is observed. Migration of some excipients 
6 
6.5 
7 
Initial 1Month 2Month 3Month 
p
H
 
Time Period 
pH at accelerated Condition 
Three piece BFS Glass 
6.7 
6.75 
6.8 
6.85 
Initial 1Week 2Week 
p
H
 
Time Period 
pH at Stress Condition 
Three piece BFS Glass 
    
S. 
No. 
Containers Specification Initial 
Stress condition Accelerated condition 
1Week 2Weeks 1Month 2Months 3Months 
1 Three piece 6.8 – 7.0 6.82 6.83 6.80 6.80 6.38 6.35 
    
2 
BFS 6.8 – 7.0 
6.82 6.80 6.76 6.73 6.35 6.28 
3 Glass 6.8 – 7.0 6.82 6.82 6.80 6.76 6.38 6.30 
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such as antioxidants, stabilizers, catalysts, plasticizers, lubricants, solvents and/or 
dyes from container to the drug product may hamper the pH of the solution. Though 
pH of solution in all containers was in specification range but it seems more stable 
in Three piece containers as compared to others. Decrease in the pH may cause the 
precipitation of drug, irritation of eye surface when applied. Ultimately it will affect 
shelf life of the product. 
 Osmolality : 
 Osmolality is the function of the number of particles present in the solution. 
Any deviation in osmolality will reflect in the breakdown of drug molecule or any 
other excipients. It may be the reflection of leachables that may be added to solution 
from the wall of container. The results for the osmolality are tabulated as follows. 
Table 27: Osmolality observations 
 
 
Fig 25: Graphical representation of Osmolality profile 
From the above results and graphical representation it is observed that there was 
increase in the osmolality of solution in each type of container. Results show that at 
accelerated condition osmolality of solution in Three piece container was increased 
from 292 mOsm (initial) to 310 mOsm at 3 month. In BFS containers it was 
S. 
 
No. 
Containe
r 
Specification Initial 
Stress condition Accelerated condition 
1Week 
2Week
s 
1Month 
2Month
s 
3Month
s 
1 
Three 
piece 
274 mOsm/kg 292 304 316 297 299 310 
    2 BFS 274 mOsm/kg 292 307 320 316 334 339 
3 Glass 274 mOsm/kg 292 302 311 317 319 324 
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increased to 339 mOsm and in glass container it was increased to 324 mOsm. At 
stress condition Osmolality in BFS container is more than the Osmolality at 
accelerated condition. This indicates that BFS container may not withstand higher 
temperature. 
 In BFS and glass containers there may be more decomposition of the 
formulation components or leaching from the containers. Timolol maleate 
ophthalmic solution formulation contains Sodium hydroxide. This Sodium 
hydroxide may attack on cross linkage of polymer. This alkylic reaction causes the 
breakdown of the component of polymer which migrates into the solution. This 
phenomenon may be the reason behind the increase in the Osmolality. 
 Drop size :  
                   The drop size was estimated on average weight basis of drops of 
ophthalmic solution by using the CPA224S, Sartorius balance. The results obtained 
are tabulated as follows.  
Table 28: Drop size of Three Piece and BFS container observations 
   Sr. 
No. 
Containers 
Initial 
Accelerated condition 
1Month 2Months 3Months 
1 Three piece 50 49 45 48 
     2 BFS 50 48 52 53 
 
 
         Fig 26: Graphical representation of Drop size 
From the above results it has been found that up to third month in accelerated 
condition drop size of BFS containers (53 µl) was comparatively more increased 
than Three piece container(48 µl). Increase in drop size may be caused due to 
widening of the nozzle aperture or thinning of the solution. In case of BFS container 
whole structure is intact made of same composition of polymer. Polymer used in 
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BFS container was less rigid as compared to three piece container. In case of three 
piece container nozzles are made up of same polymer used for body but contains 
additional ingredients which increases the rigidity of nozzle. Thus at accelerated 
condition of stability softening and widening of nozzle aperture easily takes place in 
case of BFS container. Hence there was an increase in the drop size of BFS 
container.  
It has been suggested that a decrease in drop size, would reduce the amount of 
overflow, the rate of drug loss through the drainage, the incidence of systemic side 
effects and the cost of therapy. 
 
 Water Loss Study:  
       Water loss study was performed for LDPE containers as they are semi - 
permeable in nature. Percentage water loss from semi permeable containers is the 
function of loss of aqueous phase of formulation under the condition of temperature 
and humidity i.e. 40
0
C/25% RH. 5 containers of each type i.e. Three  piece and BFS 
were placed in upright position for water loss. The results obtained are as follows. 
 
 
Table 29: Water Loss Study- Three Piece Containers 
Container 
No. 
Initial 
weight of 
the 
container(g) 
One 
Month 
% 
Loss 
Two 
Months 
% loss 
Three 
months 
% 
Loss 
1 10.5390 10.4796 0.5636 10.4707 0.6481 10.4562 0.7857 
2 10.5321 10.4700 0.5896 10.4613 0.6722 10.4492 0.7871 
3 10.4951 10.4521 0.4097 10.4433 0.4936 10.4308 0.6127 
4 10.6479 10.5686 0.7447 10.5580 0.8443 10.5428 0.9870 
5 10.4737 10.4016 0.6883 10.3929 0.7715 10.3808 0.8870 
Average 10.5376 10.4744 0.5992 10.4652 0.6859 10.4520 0.8119 
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Table 30: Water Loss Study- BFS Containers 
Container 
No. 
Initial 
weight of 
the 
container(g) 
One 
Month 
% 
Loss 
Two 
Months 
% 
loss 
Three 
months 
% 
Loss 
1 8.3646 8.2941 0.8428 8.2867 0.9313 8.2768 1.0497 
2 7.7248 7.6633 0.7961 7.6547 0.9075 7.6431 1.0576 
3 7.9372 7.8680 0.8718 7.8571 1.0092 7.8422 1.1969 
4 8.0603 7.9944 0.8175 7.8922 2.0855 7.5732 6.0432 
5 8.1179 8.0543 0.7834 8.0352 1.0187 8.0226 1.1739 
Average 8.0410 7.9748 0.8223 7.9452 1.1904 7.8716 2.1043 
 
 
 
 
 
 
 
               
 
Fig 27: Graphical representation of Water loss from containers 
 
From the above results it was found that for three piece containers average 
percentage water loss at one month, two month, and three month was 0.5992%, 
0.6859%, 0.8119% respectively where as for BFS containers water loss was 
0.8223%, 1.1904%, and 2.1043 % respectively. 
Though the both type of containers passed the criteria of water loss i.e. not more 
than 5.0%. BFS containers are showing the more water loss up to 2.1043% and three 
piece containers are showing water loss just up to 0.8119%. Environmental stress 
cracking resistance (ESCR) number of Three piece container (PE 1840 H) is higher 
than ESCR number of BFS (PE 3020 D) container.  
Hence there may be more cracking and increased permeability in case of BFS 
container as compared to the Three piece container.  
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Hence it can be concluded that the MOC of BFS container is more semi 
permeable as compared to the Three piece container’s MOC. Water loss from the 
semi- permeable containers may hamper the drug content and preservative content. 
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8. SUMMARY AND CONCLUSION 
 
I. SUMMARY 
 Ophthalmic preparations are specialized dosage forms designed to be 
instilled onto the external surface of eye (topical), administered inside (intraocular), 
adjacent to the eye (periocular) or used in conjunction with any special device.  
 Ophthalmic preparations are similar to parenteral dosage form in their 
requirements for sterility as well as consideration for osmotic pressure (tonicity), 
preservation, and tissue compatibility, avoidance of pyrogens and particulate matter 
and suitable packaging. Ophthalmic solutions are most often multidose product 
containing suitable preservative(s) to meet compendial Preservative Efficacy Test 
(USP, Ph Eu, JP) requirements. 
  There are several ophthalmic preparations, but ophthalmic solution was 
selected for study because solutions are most widely dosage form among the 
ophthalmics. Ophthalmic solution has several advantages like easy manufacturing, 
low cost, better dose uniformity,  more ocular bioavailability, Improved ratio of 
local activity versus systemic effects, not induce a foreign-body sensation, long-
lasting blurring, or a very bad aftertaste, sterilizable at industrial scale by a 
recognized process, compatible with an efficient antimicrobial preservative, or 
packaging.  
 Drug selected for the study, Timolol is a first-generation Beta blockers have 
effective action by the reduction of intra ocular pressure in Chronic open angle 
glaucoma, as well as in the treatment of Hypertension. Compared with other β- 
blockers, this drug has broader clinical applications in the treatment of Glaucoma. 
   Important factors to be considered in formulating an ophthalmic solution 
includes Clarity, Sterility, Osmolarity, pH, buffering, preservative, Solubility, 
Stability in appropriate vehicle. Viscosity, Suitable packaging and storage of 
finished product. 
  Benzalkonium chloride, a popular preservative for pharmaceutical 
products, is a complex mixture since the alkyl portion of the molecule is derived 
from natural sources. The chain lengths are principally C12 to C16, however the 
antimicrobial activity increases with the proportion of longer chain lengths. 
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Unfortunately the tendency to adsorb plastics also increases with chain length i.e. 
the most effective constituents of the mixture may be preferentially adsorbed. 
  Method preferred for sterilization of the ophthalmic solution was 
filtration sterilization. 
  Containers commonly used for ophthalmic products include glass 
containers, and polyethylene containers. Glass containers and polyethylene 
containers are said to be superior in maintaining stability of ophthalmic preparations. 
  Amber glass containers are often used where the product is suspected 
of being a light sensitive. The amber color is imparted by addition of iron and 
manganese oxides. 
  Plastic dropper bottle have been favored because they weight loss, 
are more resistant to shock and other mechanical influences, cost less and offer more 
design possibilities. Polyethylenes, that is, low density polyethylene with or without 
additives. 
 BFS containers are manufactured by Blow-Fill-Seal (BFS) technology. 
  Three Piece Container name itself indicates system contains three 
components viz... body, nozzle, and cap. Out of which, body and nozzle are made up 
of various grades of polymers of low density polyethylene whereas caps are made 
up of high density polyethylene. 
  The aim of the present study was to formulate a formulation for 
Timolol maleate (0.5%) ophthalmic solution using different concentration of 
Benzalkonium chloride as preservative. While reducing the concentration of 
Benzalkonium chloride it must be keep in mind that added quantity of preservative 
must meet compendial requirement of Preservative Efficacy Testing. 
  The present research work was also planned to provide the data about 
the selection of suitable primary packaging material for Timolol maleate (0.5%) 
ophthalmic solution to achieve the better stability during the shelf life of the product. 
As there are several factors responsible for the incompatibility of packaging material 
with the product, most suitable packaging material must be selected. 
  The proposed formula was optimized by varying the concentration of 
Benzalkonium chloride. The quantities of Timolol maleate and other excipients were 
kept constant. As the aim of the present study was to optimize the concentration of 
BKC in formulation for Timolol maleate (0.5%) ophthalmic solution. Batches were 
planned by taking different concentrations viz.0.0 % v/v,  0.01%,0.012%, 0.016%, 
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and 0.02% ,0.024 % v/v of Benzalkonium chloride. For all six batches Preservative 
Efficacy Testing was carried out according to British Pharmacopoeia. 
  After performing Preservative efficacy testing, optimized batch was 
filled into three types of container and were subjected to accelerated conditions. 
 Accelerated condition for semi-permeable containers (40ºC ± 2ºC/ NMT 
25%) and for glass containers (40ºC ± 2ºC/ 75% ± 5% RH) were chosen for storage 
for stability/compatibility study. Finished product was analyzed for the parameters 
Appearance, Assay of Timolol maleate and Benzalkonium chloride, pH, Osmolality, 
drop size, and water loss. 
   
II. CONCLUSION 
1. From the results of Preservative efficacy test, it was found that 
Benzalkonium chloride (0.02% v/v) and (0.024% v/v) showed 2 log 
reductions at 6 hours and 5 log reductions at 24 hours and no recovery at 28
th
 
day for bacteria. For fungi it showed log reduction as stated in criteria, 2 log 
reductions at 7
th
 day and no recovery at 28
th
 day. Both these concentrations 
passed the criteria according to British Pharmacopoeia. As the aim of study 
was to minimize the concentration, it will be preferable to use 0.02% v/v 
concentration of BKC in Timolol maleate 0.5% ophthalmic solution. 
2. In case of container compatibility study, results for Assay of Timolol maleate 
and Benzalkonium chloride, pH, Osmolality, drop size and water loss are 
within range of specifications for Three piece containers, BFS containers and 
Glass containers. But Three piece containers showed better results for 
compatibility with Timolol ophthalmic solution as compared to the BFS and 
Glass containers. Therefore Three piece containers (Low density 
polyethylene, PE 1840 H) are the best containers for Timolol maleate (0.5%) 
ophthalmic solution. 
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III. FUTURE SCOPE 
Future scope for the present dissertation work is as follows 
1. Eye irritation test 
2. Formulation development with newer preservative system like ‘SOFZIA’ 
(Containing propylene glycol, sorbitol, boric acid and zinc oxide). 
3. Formulation development with drug release retarding agent. 
4. Use of Three Piece container using different grades of low density 
polyethylene polymer. 
5. Introduction of calculated dose dispensing container. 
6. Intermediate and long term stability study with Three Piece containers.  
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